



Clinical trial results:

Efficacy and safety of 3 doses of S 47445 versus placebo in patients with Alzheimer's disease at mild to moderate stages with depressive symptoms. A 24-week international, multi-centre, randomized, double-blind, placebo-controlled phase II study in monotherapy followed by an optional 28-week extension period in co-administration with donepezil.

Summary

EudraCT number	2014-001519-38
Trial protocol	DE CZ HU BG SK
Global end of trial date	20 September 2017

Results information

Result version number	v1 (current)
This version publication date	18 July 2018
First version publication date	18 July 2018

Trial information

Trial identification

Sponsor protocol code	CL2-47445-011
-----------------------	---------------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT02626572
WHO universal trial number (UTN)	U1111-1156-1378

Notes:

Sponsors

Sponsor organisation name	Institut de Recherches Internationales Servier
Sponsor organisation address	50 rue Carnot, Suresnes, France, 92284
Public contact	Clinical Studies Department, Institut de Recherches Internationales Servier, 33 0155724366, clinicaltrials@servier.com
Scientific contact	Clinical Studies Department, Institut de Recherches Internationales Servier, 33 0155724366, clinicaltrials@servier.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	20 September 2017
Is this the analysis of the primary completion data?	Yes
Primary completion date	20 September 2017
Global end of trial reached?	Yes
Global end of trial date	20 September 2017
Was the trial ended prematurely?	Yes

Notes:

General information about the trial

Main objective of the trial:

Assessment of efficacy of 3 doses of S 47445 versus placebo on cognitive performance measured with the 11-item ADAS-Cog after 24 weeks of treatment.

Protection of trial subjects:

This study was conducted in accordance with Good Clinical Practice standards, ethical principles stated in the Declaration of Helsinki and applicable regulatory requirements. After the subject has ended his/her participation in the trial, the investigator provided appropriate medication and/or arranged access to appropriate care for the patient.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	13 February 2015
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects**Subjects enrolled per country**

Country: Number of subjects enrolled	Poland: 37
Country: Number of subjects enrolled	Slovakia: 11
Country: Number of subjects enrolled	Bulgaria: 56
Country: Number of subjects enrolled	Czech Republic: 66
Country: Number of subjects enrolled	Germany: 32
Country: Number of subjects enrolled	Hungary: 63
Country: Number of subjects enrolled	Brazil: 48
Country: Number of subjects enrolled	Chile: 83
Country: Number of subjects enrolled	Japan: 4
Country: Number of subjects enrolled	Mexico: 28
Country: Number of subjects enrolled	Russian Federation: 73
Country: Number of subjects enrolled	South Africa: 19
Worldwide total number of subjects	520
EEA total number of subjects	265

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	100
From 65 to 84 years	415
85 years and over	5

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

Male or female patients aged from 55 to 85 years suffering from mild to moderate Alzheimer's disease (AD) with depressive symptoms.

Period 1

Period 1 title	24-week treatment period (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Monitor, Data analyst, Carer, Assessor

Arms

Are arms mutually exclusive?	Yes
Arm title	S 47445 5 mg

Arm description: -

Arm type	Experimental
Investigational medicinal product name	S 47445 5 mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

1 tablet of S47445 5 mg was administered once a day during breakfast with a glass of water.

Arm title	S 47445 15 mg
------------------	---------------

Arm description: -

Arm type	Experimental
Investigational medicinal product name	S 47445 15 mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

1 tablet of S47445 15 mg was administered once a day during breakfast with a glass of water.

Arm title	S 47445 50 mg
------------------	---------------

Arm description: -

Arm type	Experimental
Investigational medicinal product name	S 47445 50 mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

1 tablet of S47445 50 mg was administered once a day during breakfast with a glass of water.

Arm title	Placebo
------------------	---------

Arm description: -	
Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

1 tablet of placebo was administered once a day during breakfast with a glass of water.

Number of subjects in period 1	S 47445 5 mg	S 47445 15 mg	S 47445 50 mg
Started	129	130	132
Completed	120	116	116
Not completed	9	14	16
Adverse event, serious fatal	-	1	2
Adverse event, non-fatal	1	5	5
Lost to follow-up	1	-	-
Non-medical reason	6	7	5
Lack of efficacy	1	1	3
Protocol deviation	-	-	1

Number of subjects in period 1	Placebo
Started	129
Completed	119
Not completed	10
Adverse event, serious fatal	3
Adverse event, non-fatal	3
Lost to follow-up	-
Non-medical reason	4
Lack of efficacy	-
Protocol deviation	-

Baseline characteristics

Reporting groups

Reporting group title	S 47445 5 mg
Reporting group description: -	
Reporting group title	S 47445 15 mg
Reporting group description: -	
Reporting group title	S 47445 50 mg
Reporting group description: -	
Reporting group title	Placebo
Reporting group description: -	

Reporting group values	S 47445 5 mg	S 47445 15 mg	S 47445 50 mg
Number of subjects	129	130	132
Age categorical Units: Subjects			

Age continuous Units: years arithmetic mean standard deviation	72.2 ± 7.3	71.7 ± 7.7	71.8 ± 6.6
Gender categorical Units: Subjects			
Female	82	96	95
Male	47	34	37

Reporting group values	Placebo	Total	
Number of subjects	129	520	
Age categorical Units: Subjects			

Age continuous Units: years arithmetic mean standard deviation	71.4 ± 7.7	-	
Gender categorical Units: Subjects			
Female	90	363	
Male	39	157	

End points

End points reporting groups

Reporting group title	S 47445 5 mg
Reporting group description: -	
Reporting group title	S 47445 15 mg
Reporting group description: -	
Reporting group title	S 47445 50 mg
Reporting group description: -	
Reporting group title	Placebo
Reporting group description: -	

Primary: 11-item ADAS-Cog total score

End point title	11-item ADAS-Cog total score
End point description:	
End point type	Primary
End point timeframe:	
The main analytical approach was the change from baseline to week 24.	

End point values	S 47445 5 mg	S 47445 15 mg	S 47445 50 mg	Placebo
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	120	118	121	121
Units: No unit				
arithmetic mean (standard deviation)	-0.20 (\pm 4.91)	-0.74 (\pm 5.43)	-0.05 (\pm 5.82)	0.35 (\pm 5.53)

Statistical analyses

Statistical analysis title	Primary analysis
Statistical analysis description:	
All the longitudinal observations at each post-baseline visit during the 24-week treatment period were considered.	
Comparison groups	S 47445 5 mg v Placebo
Number of subjects included in analysis	241
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Mean difference (final values)
Point estimate	-0.47
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.83
upper limit	0.89

Variability estimate	Standard deviation
Dispersion value	0.69

Statistical analysis title	Primary analysis
-----------------------------------	------------------

Statistical analysis description:

All the longitudinal observations at each post-baseline visit during the 24-week treatment period were considered.

Comparison groups	S 47445 15 mg v Placebo
Number of subjects included in analysis	239
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Mean difference (final values)
Point estimate	-0.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.26
upper limit	0.46
Variability estimate	Standard deviation
Dispersion value	0.69

Statistical analysis title	Primary analysis
-----------------------------------	------------------

Statistical analysis description:

All the longitudinal observations at each post-baseline visit during the 24-week treatment period were considered.

Comparison groups	S 47445 50 mg v Placebo
Number of subjects included in analysis	242
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Mean difference (final values)
Point estimate	-0.34
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.7
upper limit	1.01
Variability estimate	Standard deviation
Dispersion value	0.69

Adverse events

Adverse events information

Timeframe for reporting adverse events:

All adverse events that occurred or worsened or became serious during the treatment periods defined as below.

Adverse event reporting additional description:

Between the first and the last study drug intake date (both included) during the 24-week mandatory treatment period,

Between the first and the last study drug intake + 15 days (both included) during the 28-week optional extension treatment period and during the 52-week treatment period.

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
Dictionary version	20

Reporting groups

Reporting group title	S 47445 5 mg - W0-W24
Reporting group description: -	
Reporting group title	S 47445 15 mg - W0-W24
Reporting group description: -	
Reporting group title	S 47445 50 mg - W0-W24
Reporting group description: -	
Reporting group title	Placebo - W0-W24
Reporting group description: -	
Reporting group title	S 47445 5 mg - W24-W52
Reporting group description: -	
Reporting group title	S 47445 15 mg - W24-W52
Reporting group description: -	
Reporting group title	S 47445 50 mg - W24-W52
Reporting group description: -	
Reporting group title	Placebo - W24-W52
Reporting group description: -	
Reporting group title	S 47445 5 mg - W0-W52
Reporting group description: -	
Reporting group title	S 47445 15 mg - W0-W52
Reporting group description: -	
Reporting group title	S 47445 50 mg - W0-W52
Reporting group description: -	
Reporting group title	Placebo - W0-W52
Reporting group description: -	

Serious adverse events	S 47445 5 mg - W0-W24	S 47445 15 mg - W0-W24	S 47445 50 mg - W0-W24
Total subjects affected by serious adverse events			
subjects affected / exposed	4 / 129 (3.10%)	11 / 130 (8.46%)	5 / 132 (3.79%)
number of deaths (all causes)	0	0	1
number of deaths resulting from adverse events			1

Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Basal cell carcinoma			
subjects affected / exposed	0 / 129 (0.00%)	0 / 130 (0.00%)	0 / 132 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Invasive breast carcinoma			
subjects affected / exposed	0 / 129 (0.00%)	0 / 130 (0.00%)	0 / 132 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oropharyngeal cancer stage IV			
subjects affected / exposed	0 / 129 (0.00%)	0 / 130 (0.00%)	0 / 132 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Prostate cancer			
subjects affected / exposed	0 / 129 (0.00%)	0 / 130 (0.00%)	0 / 132 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tonsil cancer			
subjects affected / exposed	0 / 129 (0.00%)	0 / 130 (0.00%)	0 / 132 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Hypertension			
subjects affected / exposed	1 / 129 (0.78%)	1 / 130 (0.77%)	0 / 132 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertensive crisis			
subjects affected / exposed	0 / 129 (0.00%)	0 / 130 (0.00%)	0 / 132 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypotension			
subjects affected / exposed	1 / 129 (0.78%)	0 / 130 (0.00%)	0 / 132 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Orthostatic hypotension			
subjects affected / exposed	0 / 129 (0.00%)	0 / 130 (0.00%)	0 / 132 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Fatigue			
subjects affected / exposed	0 / 129 (0.00%)	1 / 130 (0.77%)	0 / 132 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gait disturbance			
subjects affected / exposed	0 / 129 (0.00%)	0 / 130 (0.00%)	0 / 132 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General physical health deterioration			
subjects affected / exposed	0 / 129 (0.00%)	0 / 130 (0.00%)	0 / 132 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Multiple organ dysfunction syndrome			
subjects affected / exposed	0 / 129 (0.00%)	0 / 130 (0.00%)	1 / 132 (0.76%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Non-cardiac chest pain			
subjects affected / exposed	0 / 129 (0.00%)	0 / 130 (0.00%)	0 / 132 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
Cystocele			
subjects affected / exposed	0 / 129 (0.00%)	0 / 130 (0.00%)	0 / 132 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Bronchitis chronic			

subjects affected / exposed	0 / 129 (0.00%)	0 / 130 (0.00%)	0 / 132 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chronic obstructive pulmonary disease			
subjects affected / exposed	0 / 129 (0.00%)	0 / 130 (0.00%)	0 / 132 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			
subjects affected / exposed	0 / 129 (0.00%)	0 / 130 (0.00%)	0 / 132 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary fibrosis			
subjects affected / exposed	0 / 129 (0.00%)	0 / 130 (0.00%)	0 / 132 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Aggression			
subjects affected / exposed	0 / 129 (0.00%)	2 / 130 (1.54%)	1 / 132 (0.76%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anxiety			
subjects affected / exposed	0 / 129 (0.00%)	1 / 130 (0.77%)	0 / 132 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Confusional state			
subjects affected / exposed	0 / 129 (0.00%)	0 / 130 (0.00%)	1 / 132 (0.76%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Delirium			
subjects affected / exposed	0 / 129 (0.00%)	2 / 130 (1.54%)	0 / 132 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Delusion			

subjects affected / exposed	0 / 129 (0.00%)	1 / 130 (0.77%)	0 / 132 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Depression			
subjects affected / exposed	0 / 129 (0.00%)	0 / 130 (0.00%)	1 / 132 (0.76%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hallucination, visual			
subjects affected / exposed	0 / 129 (0.00%)	0 / 130 (0.00%)	0 / 132 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Major depression			
subjects affected / exposed	0 / 129 (0.00%)	1 / 130 (0.77%)	0 / 132 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Middle insomnia			
subjects affected / exposed	0 / 129 (0.00%)	0 / 130 (0.00%)	0 / 132 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Suicidal ideation			
subjects affected / exposed	0 / 129 (0.00%)	1 / 130 (0.77%)	1 / 132 (0.76%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Blood creatine phosphokinase increased			
subjects affected / exposed	0 / 129 (0.00%)	0 / 130 (0.00%)	0 / 132 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Electrocardiogram abnormal			
subjects affected / exposed	0 / 129 (0.00%)	0 / 130 (0.00%)	0 / 132 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			

Brain contusion			
subjects affected / exposed	1 / 129 (0.78%)	0 / 130 (0.00%)	0 / 132 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fall			
subjects affected / exposed	3 / 129 (2.33%)	1 / 130 (0.77%)	0 / 132 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Foot fracture			
subjects affected / exposed	0 / 129 (0.00%)	0 / 130 (0.00%)	0 / 132 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Humerus fracture			
subjects affected / exposed	0 / 129 (0.00%)	0 / 130 (0.00%)	0 / 132 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower limb fracture			
subjects affected / exposed	0 / 129 (0.00%)	0 / 130 (0.00%)	0 / 132 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lumbar vertebral fracture			
subjects affected / exposed	0 / 129 (0.00%)	0 / 130 (0.00%)	0 / 132 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rib fracture			
subjects affected / exposed	0 / 129 (0.00%)	0 / 130 (0.00%)	0 / 132 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Seroma			
subjects affected / exposed	0 / 129 (0.00%)	0 / 130 (0.00%)	0 / 132 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subarachnoid haemorrhage			

subjects affected / exposed	0 / 129 (0.00%)	0 / 130 (0.00%)	0 / 132 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subcutaneous haematoma			
subjects affected / exposed	0 / 129 (0.00%)	0 / 130 (0.00%)	0 / 132 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Traumatic intracranial haemorrhage			
subjects affected / exposed	0 / 129 (0.00%)	0 / 130 (0.00%)	0 / 132 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wrist fracture			
subjects affected / exposed	0 / 129 (0.00%)	0 / 130 (0.00%)	0 / 132 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Acute coronary syndrome			
subjects affected / exposed	0 / 129 (0.00%)	0 / 130 (0.00%)	0 / 132 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute myocardial infarction			
subjects affected / exposed	0 / 129 (0.00%)	0 / 130 (0.00%)	0 / 132 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Angina pectoris			
subjects affected / exposed	0 / 129 (0.00%)	0 / 130 (0.00%)	0 / 132 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aortic valve incompetence			
subjects affected / exposed	0 / 129 (0.00%)	0 / 130 (0.00%)	0 / 132 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aortic valve sclerosis			

subjects affected / exposed	0 / 129 (0.00%)	0 / 130 (0.00%)	0 / 132 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrial fibrillation			
subjects affected / exposed	0 / 129 (0.00%)	1 / 130 (0.77%)	0 / 132 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrial flutter			
subjects affected / exposed	0 / 129 (0.00%)	1 / 130 (0.77%)	0 / 132 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bradycardia			
subjects affected / exposed	0 / 129 (0.00%)	0 / 130 (0.00%)	0 / 132 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac failure			
subjects affected / exposed	0 / 129 (0.00%)	0 / 130 (0.00%)	0 / 132 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac failure chronic			
subjects affected / exposed	0 / 129 (0.00%)	1 / 130 (0.77%)	0 / 132 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mitral valve incompetence			
subjects affected / exposed	0 / 129 (0.00%)	0 / 130 (0.00%)	0 / 132 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mitral valve sclerosis			
subjects affected / exposed	0 / 129 (0.00%)	0 / 130 (0.00%)	0 / 132 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myocardial infarction			

subjects affected / exposed	0 / 129 (0.00%)	0 / 130 (0.00%)	0 / 132 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myocardial ischaemia			
subjects affected / exposed	0 / 129 (0.00%)	1 / 130 (0.77%)	0 / 132 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tricuspid valve incompetence			
subjects affected / exposed	0 / 129 (0.00%)	0 / 130 (0.00%)	0 / 132 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Amimia			
subjects affected / exposed	0 / 129 (0.00%)	0 / 130 (0.00%)	0 / 132 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bradykinesia			
subjects affected / exposed	0 / 129 (0.00%)	0 / 130 (0.00%)	0 / 132 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cogwheel rigidity			
subjects affected / exposed	0 / 129 (0.00%)	0 / 130 (0.00%)	0 / 132 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coma			
subjects affected / exposed	0 / 129 (0.00%)	0 / 130 (0.00%)	0 / 132 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dementia with Lewy bodies			
subjects affected / exposed	0 / 129 (0.00%)	0 / 130 (0.00%)	0 / 132 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dizziness			

subjects affected / exposed	0 / 129 (0.00%)	0 / 130 (0.00%)	0 / 132 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhagic stroke			
subjects affected / exposed	0 / 129 (0.00%)	0 / 130 (0.00%)	0 / 132 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ischaemic stroke			
subjects affected / exposed	0 / 129 (0.00%)	0 / 130 (0.00%)	1 / 132 (0.76%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Loss of consciousness			
subjects affected / exposed	1 / 129 (0.78%)	0 / 130 (0.00%)	0 / 132 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sciatica			
subjects affected / exposed	0 / 129 (0.00%)	0 / 130 (0.00%)	1 / 132 (0.76%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subdural hygroma			
subjects affected / exposed	1 / 129 (0.78%)	0 / 130 (0.00%)	0 / 132 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Syncope			
subjects affected / exposed	1 / 129 (0.78%)	0 / 130 (0.00%)	0 / 132 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subarachnoid haemorrhage			
alternative dictionary used: MedDRA 19			
subjects affected / exposed	1 / 129 (0.78%)	0 / 130 (0.00%)	0 / 132 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			

Haemorrhagic anaemia			
subjects affected / exposed	0 / 129 (0.00%)	1 / 130 (0.77%)	0 / 132 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombocytopenia			
subjects affected / exposed	0 / 129 (0.00%)	0 / 130 (0.00%)	0 / 132 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			
Macular degeneration			
subjects affected / exposed	0 / 129 (0.00%)	1 / 130 (0.77%)	0 / 132 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal discomfort			
subjects affected / exposed	0 / 129 (0.00%)	0 / 130 (0.00%)	0 / 132 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis			
subjects affected / exposed	0 / 129 (0.00%)	0 / 130 (0.00%)	0 / 132 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Constipation			
subjects affected / exposed	0 / 129 (0.00%)	0 / 130 (0.00%)	0 / 132 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Duodenal ulcer haemorrhage			
subjects affected / exposed	0 / 129 (0.00%)	1 / 130 (0.77%)	0 / 132 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dysphagia			
subjects affected / exposed	0 / 129 (0.00%)	0 / 130 (0.00%)	0 / 132 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Faecaloma			
subjects affected / exposed	0 / 129 (0.00%)	0 / 130 (0.00%)	0 / 132 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastritis erosive			
subjects affected / exposed	0 / 129 (0.00%)	0 / 130 (0.00%)	0 / 132 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal haemorrhage			
subjects affected / exposed	0 / 129 (0.00%)	0 / 130 (0.00%)	0 / 132 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhoidal haemorrhage			
subjects affected / exposed	0 / 129 (0.00%)	0 / 130 (0.00%)	0 / 132 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Inguinal hernia			
subjects affected / exposed	0 / 129 (0.00%)	0 / 130 (0.00%)	0 / 132 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Large intestine polyp			
subjects affected / exposed	0 / 129 (0.00%)	0 / 130 (0.00%)	0 / 132 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Melaena			
subjects affected / exposed	0 / 129 (0.00%)	0 / 130 (0.00%)	0 / 132 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	0 / 129 (0.00%)	0 / 130 (0.00%)	1 / 132 (0.76%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal failure			

subjects affected / exposed	0 / 129 (0.00%)	0 / 130 (0.00%)	1 / 132 (0.76%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Lumbar spinal stenosis			
subjects affected / exposed	1 / 129 (0.78%)	0 / 130 (0.00%)	0 / 132 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteoarthritis			
subjects affected / exposed	0 / 129 (0.00%)	1 / 130 (0.77%)	0 / 132 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pain in extremity			
subjects affected / exposed	0 / 129 (0.00%)	0 / 130 (0.00%)	0 / 132 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Diverticulitis			
subjects affected / exposed	0 / 129 (0.00%)	0 / 130 (0.00%)	0 / 132 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mastoiditis			
subjects affected / exposed	0 / 129 (0.00%)	0 / 130 (0.00%)	0 / 132 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Otitis media			
subjects affected / exposed	0 / 129 (0.00%)	0 / 130 (0.00%)	0 / 132 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	1 / 129 (0.78%)	0 / 130 (0.00%)	0 / 132 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Postoperative wound infection			
subjects affected / exposed	0 / 129 (0.00%)	1 / 130 (0.77%)	0 / 132 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis			
subjects affected / exposed	0 / 129 (0.00%)	0 / 130 (0.00%)	0 / 132 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory tract infection			
subjects affected / exposed	0 / 129 (0.00%)	0 / 130 (0.00%)	0 / 132 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	0 / 129 (0.00%)	0 / 130 (0.00%)	1 / 132 (0.76%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Septic shock			
subjects affected / exposed	0 / 129 (0.00%)	0 / 130 (0.00%)	0 / 132 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	0 / 129 (0.00%)	0 / 130 (0.00%)	0 / 132 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wound infection staphylococcal			
subjects affected / exposed	0 / 129 (0.00%)	1 / 130 (0.77%)	0 / 132 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	0 / 129 (0.00%)	1 / 130 (0.77%)	0 / 132 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperkalaemia			

subjects affected / exposed	0 / 129 (0.00%)	1 / 130 (0.77%)	0 / 132 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Placebo - W0-W24	S 47445 5 mg - W24-W52	S 47445 15 mg - W24-W52
Total subjects affected by serious adverse events			
subjects affected / exposed	6 / 129 (4.65%)	8 / 119 (6.72%)	16 / 115 (13.91%)
number of deaths (all causes)	1	0	1
number of deaths resulting from adverse events	1		1
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Basal cell carcinoma			
subjects affected / exposed	0 / 129 (0.00%)	1 / 119 (0.84%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Invasive breast carcinoma			
subjects affected / exposed	0 / 129 (0.00%)	0 / 119 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oropharyngeal cancer stage IV			
subjects affected / exposed	0 / 129 (0.00%)	0 / 119 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Prostate cancer			
subjects affected / exposed	0 / 129 (0.00%)	1 / 119 (0.84%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tonsil cancer			
subjects affected / exposed	0 / 129 (0.00%)	0 / 119 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Hypertension			

subjects affected / exposed	0 / 129 (0.00%)	0 / 119 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertensive crisis			
subjects affected / exposed	0 / 129 (0.00%)	0 / 119 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypotension			
subjects affected / exposed	0 / 129 (0.00%)	0 / 119 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Orthostatic hypotension			
subjects affected / exposed	0 / 129 (0.00%)	1 / 119 (0.84%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Fatigue			
subjects affected / exposed	0 / 129 (0.00%)	0 / 119 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gait disturbance			
subjects affected / exposed	1 / 129 (0.78%)	0 / 119 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General physical health deterioration			
subjects affected / exposed	0 / 129 (0.00%)	0 / 119 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Multiple organ dysfunction syndrome			
subjects affected / exposed	0 / 129 (0.00%)	0 / 119 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Non-cardiac chest pain			

subjects affected / exposed	0 / 129 (0.00%)	0 / 119 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
Cystocele			
subjects affected / exposed	0 / 129 (0.00%)	0 / 119 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Bronchitis chronic			
subjects affected / exposed	0 / 129 (0.00%)	0 / 119 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chronic obstructive pulmonary disease			
subjects affected / exposed	0 / 129 (0.00%)	0 / 119 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			
subjects affected / exposed	0 / 129 (0.00%)	0 / 119 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary fibrosis			
subjects affected / exposed	0 / 129 (0.00%)	0 / 119 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Aggression			
subjects affected / exposed	0 / 129 (0.00%)	1 / 119 (0.84%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anxiety			

subjects affected / exposed	0 / 129 (0.00%)	0 / 119 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Confusional state			
subjects affected / exposed	0 / 129 (0.00%)	1 / 119 (0.84%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Delirium			
subjects affected / exposed	1 / 129 (0.78%)	0 / 119 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Delusion			
subjects affected / exposed	0 / 129 (0.00%)	0 / 119 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Depression			
subjects affected / exposed	0 / 129 (0.00%)	0 / 119 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hallucination, visual			
subjects affected / exposed	1 / 129 (0.78%)	0 / 119 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Major depression			
subjects affected / exposed	0 / 129 (0.00%)	0 / 119 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Middle insomnia			
subjects affected / exposed	0 / 129 (0.00%)	1 / 119 (0.84%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Suicidal ideation			

subjects affected / exposed	0 / 129 (0.00%)	0 / 119 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Blood creatine phosphokinase increased			
subjects affected / exposed	0 / 129 (0.00%)	0 / 119 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Electrocardiogram abnormal			
subjects affected / exposed	0 / 129 (0.00%)	0 / 119 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Brain contusion			
subjects affected / exposed	0 / 129 (0.00%)	0 / 119 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fall			
subjects affected / exposed	0 / 129 (0.00%)	0 / 119 (0.00%)	6 / 115 (5.22%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 6
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Foot fracture			
subjects affected / exposed	0 / 129 (0.00%)	0 / 119 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Humerus fracture			
subjects affected / exposed	0 / 129 (0.00%)	0 / 119 (0.00%)	2 / 115 (1.74%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower limb fracture			
subjects affected / exposed	0 / 129 (0.00%)	0 / 119 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Lumbar vertebral fracture			
subjects affected / exposed	1 / 129 (0.78%)	0 / 119 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rib fracture			
subjects affected / exposed	0 / 129 (0.00%)	0 / 119 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Seroma			
subjects affected / exposed	0 / 129 (0.00%)	0 / 119 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subarachnoid haemorrhage			
subjects affected / exposed	0 / 129 (0.00%)	0 / 119 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subcutaneous haematoma			
subjects affected / exposed	0 / 129 (0.00%)	0 / 119 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Traumatic intracranial haemorrhage			
subjects affected / exposed	0 / 129 (0.00%)	0 / 119 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wrist fracture			
subjects affected / exposed	0 / 129 (0.00%)	0 / 119 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Acute coronary syndrome			
subjects affected / exposed	0 / 129 (0.00%)	0 / 119 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute myocardial infarction			

subjects affected / exposed	0 / 129 (0.00%)	0 / 119 (0.00%)	2 / 115 (1.74%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Angina pectoris			
subjects affected / exposed	1 / 129 (0.78%)	0 / 119 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aortic valve incompetence			
subjects affected / exposed	1 / 129 (0.78%)	0 / 119 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aortic valve sclerosis			
subjects affected / exposed	1 / 129 (0.78%)	0 / 119 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrial fibrillation			
subjects affected / exposed	1 / 129 (0.78%)	0 / 119 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrial flutter			
subjects affected / exposed	1 / 129 (0.78%)	0 / 119 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bradycardia			
subjects affected / exposed	0 / 129 (0.00%)	0 / 119 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac failure			
subjects affected / exposed	0 / 129 (0.00%)	0 / 119 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac failure chronic			

subjects affected / exposed	1 / 129 (0.78%)	0 / 119 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mitral valve incompetence			
subjects affected / exposed	1 / 129 (0.78%)	0 / 119 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mitral valve sclerosis			
subjects affected / exposed	1 / 129 (0.78%)	0 / 119 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myocardial infarction			
subjects affected / exposed	0 / 129 (0.00%)	0 / 119 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myocardial ischaemia			
subjects affected / exposed	1 / 129 (0.78%)	0 / 119 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tricuspid valve incompetence			
subjects affected / exposed	0 / 129 (0.00%)	0 / 119 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Amimia			
subjects affected / exposed	1 / 129 (0.78%)	0 / 119 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bradykinesia			
subjects affected / exposed	1 / 129 (0.78%)	0 / 119 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cogwheel rigidity			

subjects affected / exposed	1 / 129 (0.78%)	0 / 119 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coma			
subjects affected / exposed	0 / 129 (0.00%)	0 / 119 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dementia with Lewy bodies			
subjects affected / exposed	1 / 129 (0.78%)	0 / 119 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dizziness			
subjects affected / exposed	0 / 129 (0.00%)	0 / 119 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhagic stroke			
subjects affected / exposed	0 / 129 (0.00%)	0 / 119 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ischaemic stroke			
subjects affected / exposed	0 / 129 (0.00%)	0 / 119 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Loss of consciousness			
subjects affected / exposed	0 / 129 (0.00%)	0 / 119 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sciatica			
subjects affected / exposed	0 / 129 (0.00%)	0 / 119 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subdural hygroma			

subjects affected / exposed	0 / 129 (0.00%)	0 / 119 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Syncope			
subjects affected / exposed	0 / 129 (0.00%)	2 / 119 (1.68%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subarachnoid haemorrhage			
alternative dictionary used: MedDRA 19			
subjects affected / exposed	0 / 129 (0.00%)	0 / 119 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Haemorrhagic anaemia			
subjects affected / exposed	0 / 129 (0.00%)	0 / 119 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombocytopenia			
subjects affected / exposed	1 / 129 (0.78%)	0 / 119 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			
Macular degeneration			
subjects affected / exposed	0 / 129 (0.00%)	0 / 119 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal discomfort			
subjects affected / exposed	0 / 129 (0.00%)	0 / 119 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis			

subjects affected / exposed	0 / 129 (0.00%)	1 / 119 (0.84%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Constipation			
subjects affected / exposed	1 / 129 (0.78%)	0 / 119 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Duodenal ulcer haemorrhage			
subjects affected / exposed	0 / 129 (0.00%)	0 / 119 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dysphagia			
subjects affected / exposed	1 / 129 (0.78%)	0 / 119 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Faecaloma			
subjects affected / exposed	0 / 129 (0.00%)	0 / 119 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastritis erosive			
subjects affected / exposed	0 / 129 (0.00%)	0 / 119 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal haemorrhage			
subjects affected / exposed	0 / 129 (0.00%)	0 / 119 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhoidal haemorrhage			
subjects affected / exposed	0 / 129 (0.00%)	0 / 119 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Inguinal hernia			

subjects affected / exposed	0 / 129 (0.00%)	0 / 119 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Large intestine polyp			
subjects affected / exposed	0 / 129 (0.00%)	0 / 119 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Melaena			
subjects affected / exposed	0 / 129 (0.00%)	0 / 119 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	0 / 129 (0.00%)	0 / 119 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal failure			
subjects affected / exposed	0 / 129 (0.00%)	0 / 119 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Lumbar spinal stenosis			
subjects affected / exposed	0 / 129 (0.00%)	0 / 119 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteoarthritis			
subjects affected / exposed	1 / 129 (0.78%)	0 / 119 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pain in extremity			
subjects affected / exposed	0 / 129 (0.00%)	0 / 119 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Infections and infestations Diverticulitis subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 129 (0.00%) 0 / 0 0 / 0	0 / 119 (0.00%) 0 / 0 0 / 0	0 / 115 (0.00%) 0 / 0 0 / 0
Mastoiditis subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 129 (0.00%) 0 / 0 0 / 0	0 / 119 (0.00%) 0 / 0 0 / 0	1 / 115 (0.87%) 0 / 1 0 / 0
Otitis media subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 129 (0.00%) 0 / 0 0 / 0	0 / 119 (0.00%) 0 / 0 0 / 0	1 / 115 (0.87%) 0 / 1 0 / 0
Pneumonia subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 129 (0.00%) 0 / 0 0 / 0	0 / 119 (0.00%) 0 / 0 0 / 0	0 / 115 (0.00%) 0 / 0 0 / 0
Postoperative wound infection subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 129 (0.00%) 0 / 0 0 / 0	0 / 119 (0.00%) 0 / 0 0 / 0	0 / 115 (0.00%) 0 / 0 0 / 0
Pyelonephritis subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 129 (0.78%) 0 / 1 0 / 0	0 / 119 (0.00%) 0 / 0 0 / 0	0 / 115 (0.00%) 0 / 0 0 / 0
Respiratory tract infection subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 129 (0.00%) 0 / 0 0 / 0	0 / 119 (0.00%) 0 / 0 0 / 0	0 / 115 (0.00%) 0 / 0 0 / 0
Sepsis subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 129 (0.00%) 0 / 0 0 / 0	0 / 119 (0.00%) 0 / 0 0 / 0	0 / 115 (0.00%) 0 / 0 0 / 0
Septic shock			

subjects affected / exposed	0 / 129 (0.00%)	0 / 119 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	0 / 129 (0.00%)	0 / 119 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wound infection staphylococcal			
subjects affected / exposed	0 / 129 (0.00%)	0 / 119 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	0 / 129 (0.00%)	0 / 119 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperkalaemia			
subjects affected / exposed	0 / 129 (0.00%)	0 / 119 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	S 47445 50 mg - W24-W52	Placebo - W24-W52	S 47445 5 mg - W0-W52
Total subjects affected by serious adverse events			
subjects affected / exposed	10 / 115 (8.70%)	10 / 119 (8.40%)	11 / 129 (8.53%)
number of deaths (all causes)	1	2	0
number of deaths resulting from adverse events	1	2	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Basal cell carcinoma			
subjects affected / exposed	1 / 115 (0.87%)	0 / 119 (0.00%)	1 / 129 (0.78%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Invasive breast carcinoma			

subjects affected / exposed	0 / 115 (0.00%)	0 / 119 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oropharyngeal cancer stage IV			
subjects affected / exposed	1 / 115 (0.87%)	0 / 119 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Prostate cancer			
subjects affected / exposed	0 / 115 (0.00%)	0 / 119 (0.00%)	1 / 129 (0.78%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tonsil cancer			
subjects affected / exposed	1 / 115 (0.87%)	0 / 119 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Hypertension			
subjects affected / exposed	0 / 115 (0.00%)	0 / 119 (0.00%)	1 / 129 (0.78%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertensive crisis			
subjects affected / exposed	1 / 115 (0.87%)	0 / 119 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypotension			
subjects affected / exposed	0 / 115 (0.00%)	0 / 119 (0.00%)	1 / 129 (0.78%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Orthostatic hypotension			
subjects affected / exposed	0 / 115 (0.00%)	0 / 119 (0.00%)	1 / 129 (0.78%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			

Fatigue			
subjects affected / exposed	0 / 115 (0.00%)	0 / 119 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gait disturbance			
subjects affected / exposed	0 / 115 (0.00%)	0 / 119 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General physical health deterioration			
subjects affected / exposed	1 / 115 (0.87%)	0 / 119 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Multiple organ dysfunction syndrome			
subjects affected / exposed	0 / 115 (0.00%)	0 / 119 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Non-cardiac chest pain			
subjects affected / exposed	1 / 115 (0.87%)	0 / 119 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
Cystocele			
subjects affected / exposed	1 / 115 (0.87%)	0 / 119 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Bronchitis chronic			
subjects affected / exposed	0 / 115 (0.00%)	0 / 119 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chronic obstructive pulmonary disease			

subjects affected / exposed	0 / 115 (0.00%)	0 / 119 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			
subjects affected / exposed	0 / 115 (0.00%)	1 / 119 (0.84%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary fibrosis			
subjects affected / exposed	0 / 115 (0.00%)	1 / 119 (0.84%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Aggression			
subjects affected / exposed	0 / 115 (0.00%)	0 / 119 (0.00%)	1 / 129 (0.78%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anxiety			
subjects affected / exposed	0 / 115 (0.00%)	0 / 119 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Confusional state			
subjects affected / exposed	0 / 115 (0.00%)	0 / 119 (0.00%)	1 / 129 (0.78%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Delirium			
subjects affected / exposed	0 / 115 (0.00%)	0 / 119 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Delusion			
subjects affected / exposed	0 / 115 (0.00%)	0 / 119 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Depression			

subjects affected / exposed	0 / 115 (0.00%)	0 / 119 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hallucination, visual			
subjects affected / exposed	0 / 115 (0.00%)	0 / 119 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Major depression			
subjects affected / exposed	0 / 115 (0.00%)	0 / 119 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Middle insomnia			
subjects affected / exposed	0 / 115 (0.00%)	0 / 119 (0.00%)	1 / 129 (0.78%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Suicidal ideation			
subjects affected / exposed	0 / 115 (0.00%)	0 / 119 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Blood creatine phosphokinase increased			
subjects affected / exposed	0 / 115 (0.00%)	0 / 119 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Electrocardiogram abnormal			
subjects affected / exposed	1 / 115 (0.87%)	0 / 119 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Brain contusion			
subjects affected / exposed	0 / 115 (0.00%)	0 / 119 (0.00%)	1 / 129 (0.78%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Fall			
subjects affected / exposed	1 / 115 (0.87%)	2 / 119 (1.68%)	3 / 129 (2.33%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Foot fracture			
subjects affected / exposed	0 / 115 (0.00%)	0 / 119 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Humerus fracture			
subjects affected / exposed	0 / 115 (0.00%)	1 / 119 (0.84%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower limb fracture			
subjects affected / exposed	0 / 115 (0.00%)	0 / 119 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lumbar vertebral fracture			
subjects affected / exposed	0 / 115 (0.00%)	0 / 119 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rib fracture			
subjects affected / exposed	0 / 115 (0.00%)	0 / 119 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Seroma			
subjects affected / exposed	0 / 115 (0.00%)	0 / 119 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subarachnoid haemorrhage			
subjects affected / exposed	0 / 115 (0.00%)	0 / 119 (0.00%)	1 / 129 (0.78%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subcutaneous haematoma			

subjects affected / exposed	1 / 115 (0.87%)	0 / 119 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Traumatic intracranial haemorrhage			
subjects affected / exposed	0 / 115 (0.00%)	0 / 119 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wrist fracture			
subjects affected / exposed	0 / 115 (0.00%)	1 / 119 (0.84%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Acute coronary syndrome			
subjects affected / exposed	0 / 115 (0.00%)	0 / 119 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute myocardial infarction			
subjects affected / exposed	0 / 115 (0.00%)	0 / 119 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Angina pectoris			
subjects affected / exposed	0 / 115 (0.00%)	0 / 119 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aortic valve incompetence			
subjects affected / exposed	0 / 115 (0.00%)	0 / 119 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aortic valve sclerosis			
subjects affected / exposed	0 / 115 (0.00%)	0 / 119 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrial fibrillation			

subjects affected / exposed	0 / 115 (0.00%)	2 / 119 (1.68%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrial flutter			
subjects affected / exposed	0 / 115 (0.00%)	0 / 119 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bradycardia			
subjects affected / exposed	0 / 115 (0.00%)	1 / 119 (0.84%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac failure			
subjects affected / exposed	0 / 115 (0.00%)	1 / 119 (0.84%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Cardiac failure chronic			
subjects affected / exposed	0 / 115 (0.00%)	0 / 119 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mitral valve incompetence			
subjects affected / exposed	0 / 115 (0.00%)	0 / 119 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mitral valve sclerosis			
subjects affected / exposed	0 / 115 (0.00%)	0 / 119 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myocardial infarction			
subjects affected / exposed	0 / 115 (0.00%)	0 / 119 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myocardial ischaemia			

subjects affected / exposed	0 / 115 (0.00%)	0 / 119 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tricuspid valve incompetence			
subjects affected / exposed	0 / 115 (0.00%)	0 / 119 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Amimia			
subjects affected / exposed	0 / 115 (0.00%)	0 / 119 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bradykinesia			
subjects affected / exposed	0 / 115 (0.00%)	0 / 119 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cogwheel rigidity			
subjects affected / exposed	0 / 115 (0.00%)	0 / 119 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coma			
subjects affected / exposed	0 / 115 (0.00%)	0 / 119 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dementia with Lewy bodies			
subjects affected / exposed	0 / 115 (0.00%)	0 / 119 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dizziness			
subjects affected / exposed	1 / 115 (0.87%)	0 / 119 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhagic stroke			

subjects affected / exposed	1 / 115 (0.87%)	0 / 119 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ischaemic stroke			
subjects affected / exposed	0 / 115 (0.00%)	1 / 119 (0.84%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Loss of consciousness			
subjects affected / exposed	0 / 115 (0.00%)	1 / 119 (0.84%)	1 / 129 (0.78%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Sciatica			
subjects affected / exposed	0 / 115 (0.00%)	0 / 119 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subdural hygroma			
subjects affected / exposed	0 / 115 (0.00%)	0 / 119 (0.00%)	1 / 129 (0.78%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Syncope			
subjects affected / exposed	0 / 115 (0.00%)	0 / 119 (0.00%)	3 / 129 (2.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subarachnoid haemorrhage			
alternative dictionary used: MedDRA 19			
subjects affected / exposed	0 / 115 (0.00%)	0 / 119 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Haemorrhagic anaemia			
subjects affected / exposed	0 / 115 (0.00%)	0 / 119 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Thrombocytopenia			
subjects affected / exposed	0 / 115 (0.00%)	0 / 119 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			
Macular degeneration			
subjects affected / exposed	0 / 115 (0.00%)	1 / 119 (0.84%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal discomfort			
subjects affected / exposed	1 / 115 (0.87%)	0 / 119 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis			
subjects affected / exposed	0 / 115 (0.00%)	0 / 119 (0.00%)	1 / 129 (0.78%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Constipation			
subjects affected / exposed	0 / 115 (0.00%)	0 / 119 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Duodenal ulcer haemorrhage			
subjects affected / exposed	1 / 115 (0.87%)	0 / 119 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dysphagia			
subjects affected / exposed	0 / 115 (0.00%)	0 / 119 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Faecaloma			
subjects affected / exposed	1 / 115 (0.87%)	0 / 119 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Gastritis erosive			
subjects affected / exposed	1 / 115 (0.87%)	0 / 119 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal haemorrhage			
subjects affected / exposed	0 / 115 (0.00%)	0 / 119 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhoidal haemorrhage			
subjects affected / exposed	0 / 115 (0.00%)	0 / 119 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Inguinal hernia			
subjects affected / exposed	0 / 115 (0.00%)	0 / 119 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Large intestine polyp			
subjects affected / exposed	0 / 115 (0.00%)	1 / 119 (0.84%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Melaena			
subjects affected / exposed	0 / 115 (0.00%)	0 / 119 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	0 / 115 (0.00%)	0 / 119 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal failure			
subjects affected / exposed	0 / 115 (0.00%)	0 / 119 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue			

disorders			
Lumbar spinal stenosis			
subjects affected / exposed	0 / 115 (0.00%)	0 / 119 (0.00%)	1 / 129 (0.78%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteoarthritis			
subjects affected / exposed	0 / 115 (0.00%)	0 / 119 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pain in extremity			
subjects affected / exposed	1 / 115 (0.87%)	0 / 119 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Diverticulitis			
subjects affected / exposed	1 / 115 (0.87%)	0 / 119 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mastoiditis			
subjects affected / exposed	0 / 115 (0.00%)	0 / 119 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Otitis media			
subjects affected / exposed	0 / 115 (0.00%)	0 / 119 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	0 / 115 (0.00%)	1 / 119 (0.84%)	1 / 129 (0.78%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Postoperative wound infection			
subjects affected / exposed	0 / 115 (0.00%)	0 / 119 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Pyelonephritis			
subjects affected / exposed	0 / 115 (0.00%)	0 / 119 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory tract infection			
subjects affected / exposed	0 / 115 (0.00%)	1 / 119 (0.84%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	0 / 115 (0.00%)	0 / 119 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Septic shock			
subjects affected / exposed	0 / 115 (0.00%)	1 / 119 (0.84%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	0 / 115 (0.00%)	0 / 119 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wound infection staphylococcal			
subjects affected / exposed	0 / 115 (0.00%)	0 / 119 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	0 / 115 (0.00%)	0 / 119 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperkalaemia			
subjects affected / exposed	0 / 115 (0.00%)	0 / 119 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	S 47445 15 mg - W0-W52	S 47445 50 mg - W0-W52	Placebo - W0-W52
Total subjects affected by serious adverse events			
subjects affected / exposed	27 / 130 (20.77%)	16 / 132 (12.12%)	17 / 129 (13.18%)
number of deaths (all causes)	1	2	3
number of deaths resulting from adverse events	1	2	3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Basal cell carcinoma			
subjects affected / exposed	0 / 130 (0.00%)	1 / 132 (0.76%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Invasive breast carcinoma			
subjects affected / exposed	1 / 130 (0.77%)	0 / 132 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oropharyngeal cancer stage IV			
subjects affected / exposed	0 / 130 (0.00%)	1 / 132 (0.76%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Prostate cancer			
subjects affected / exposed	0 / 130 (0.00%)	0 / 132 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tonsil cancer			
subjects affected / exposed	0 / 130 (0.00%)	1 / 132 (0.76%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Hypertension			
subjects affected / exposed	1 / 130 (0.77%)	0 / 132 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertensive crisis			

subjects affected / exposed	0 / 130 (0.00%)	2 / 132 (1.52%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypotension			
subjects affected / exposed	0 / 130 (0.00%)	0 / 132 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Orthostatic hypotension			
subjects affected / exposed	0 / 130 (0.00%)	0 / 132 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Fatigue			
subjects affected / exposed	1 / 130 (0.77%)	0 / 132 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gait disturbance			
subjects affected / exposed	0 / 130 (0.00%)	0 / 132 (0.00%)	1 / 129 (0.78%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General physical health deterioration			
subjects affected / exposed	0 / 130 (0.00%)	1 / 132 (0.76%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Multiple organ dysfunction syndrome			
subjects affected / exposed	0 / 130 (0.00%)	1 / 132 (0.76%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Non-cardiac chest pain			
subjects affected / exposed	0 / 130 (0.00%)	1 / 132 (0.76%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			

Cystocele			
subjects affected / exposed	0 / 130 (0.00%)	1 / 132 (0.76%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Bronchitis chronic			
subjects affected / exposed	1 / 130 (0.77%)	0 / 132 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chronic obstructive pulmonary disease			
subjects affected / exposed	1 / 130 (0.77%)	0 / 132 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			
subjects affected / exposed	0 / 130 (0.00%)	0 / 132 (0.00%)	1 / 129 (0.78%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary fibrosis			
subjects affected / exposed	0 / 130 (0.00%)	0 / 132 (0.00%)	1 / 129 (0.78%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Aggression			
subjects affected / exposed	2 / 130 (1.54%)	1 / 132 (0.76%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anxiety			
subjects affected / exposed	1 / 130 (0.77%)	0 / 132 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Confusional state			

subjects affected / exposed	0 / 130 (0.00%)	1 / 132 (0.76%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Delirium			
subjects affected / exposed	2 / 130 (1.54%)	0 / 132 (0.00%)	1 / 129 (0.78%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Delusion			
subjects affected / exposed	1 / 130 (0.77%)	0 / 132 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Depression			
subjects affected / exposed	0 / 130 (0.00%)	1 / 132 (0.76%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hallucination, visual			
subjects affected / exposed	0 / 130 (0.00%)	0 / 132 (0.00%)	1 / 129 (0.78%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Major depression			
subjects affected / exposed	1 / 130 (0.77%)	0 / 132 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Middle insomnia			
subjects affected / exposed	0 / 130 (0.00%)	0 / 132 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Suicidal ideation			
subjects affected / exposed	1 / 130 (0.77%)	1 / 132 (0.76%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Blood creatine phosphokinase increased			

subjects affected / exposed	1 / 130 (0.77%)	0 / 132 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Electrocardiogram abnormal			
subjects affected / exposed	0 / 130 (0.00%)	1 / 132 (0.76%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Brain contusion			
subjects affected / exposed	0 / 130 (0.00%)	0 / 132 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fall			
subjects affected / exposed	7 / 130 (5.38%)	1 / 132 (0.76%)	2 / 129 (1.55%)
occurrences causally related to treatment / all	0 / 7	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Foot fracture			
subjects affected / exposed	1 / 130 (0.77%)	0 / 132 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Humerus fracture			
subjects affected / exposed	2 / 130 (1.54%)	0 / 132 (0.00%)	1 / 129 (0.78%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower limb fracture			
subjects affected / exposed	1 / 130 (0.77%)	0 / 132 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lumbar vertebral fracture			
subjects affected / exposed	0 / 130 (0.00%)	0 / 132 (0.00%)	1 / 129 (0.78%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rib fracture			

subjects affected / exposed	1 / 130 (0.77%)	0 / 132 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Seroma			
subjects affected / exposed	1 / 130 (0.77%)	0 / 132 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subarachnoid haemorrhage			
subjects affected / exposed	0 / 130 (0.00%)	0 / 132 (0.00%)	1 / 129 (0.78%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	1 / 1
Subcutaneous haematoma			
subjects affected / exposed	0 / 130 (0.00%)	1 / 132 (0.76%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Traumatic intracranial haemorrhage			
subjects affected / exposed	1 / 130 (0.77%)	0 / 132 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wrist fracture			
subjects affected / exposed	0 / 130 (0.00%)	0 / 132 (0.00%)	1 / 129 (0.78%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Acute coronary syndrome			
subjects affected / exposed	0 / 130 (0.00%)	1 / 132 (0.76%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute myocardial infarction			
subjects affected / exposed	2 / 130 (1.54%)	0 / 132 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Angina pectoris			

subjects affected / exposed	0 / 130 (0.00%)	0 / 132 (0.00%)	1 / 129 (0.78%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aortic valve incompetence			
subjects affected / exposed	0 / 130 (0.00%)	0 / 132 (0.00%)	1 / 129 (0.78%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aortic valve sclerosis			
subjects affected / exposed	0 / 130 (0.00%)	0 / 132 (0.00%)	1 / 129 (0.78%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrial fibrillation			
subjects affected / exposed	2 / 130 (1.54%)	1 / 132 (0.76%)	3 / 129 (2.33%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrial flutter			
subjects affected / exposed	1 / 130 (0.77%)	0 / 132 (0.00%)	1 / 129 (0.78%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bradycardia			
subjects affected / exposed	0 / 130 (0.00%)	0 / 132 (0.00%)	1 / 129 (0.78%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac failure			
subjects affected / exposed	1 / 130 (0.77%)	0 / 132 (0.00%)	1 / 129 (0.78%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Cardiac failure chronic			
subjects affected / exposed	1 / 130 (0.77%)	0 / 132 (0.00%)	1 / 129 (0.78%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mitral valve incompetence			

subjects affected / exposed	0 / 130 (0.00%)	0 / 132 (0.00%)	1 / 129 (0.78%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mitral valve sclerosis			
subjects affected / exposed	0 / 130 (0.00%)	0 / 132 (0.00%)	1 / 129 (0.78%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myocardial infarction			
subjects affected / exposed	0 / 130 (0.00%)	1 / 132 (0.76%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myocardial ischaemia			
subjects affected / exposed	1 / 130 (0.77%)	0 / 132 (0.00%)	1 / 129 (0.78%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tricuspid valve incompetence			
subjects affected / exposed	0 / 130 (0.00%)	1 / 132 (0.76%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Amimia			
subjects affected / exposed	0 / 130 (0.00%)	0 / 132 (0.00%)	1 / 129 (0.78%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bradykinesia			
subjects affected / exposed	0 / 130 (0.00%)	0 / 132 (0.00%)	1 / 129 (0.78%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cogwheel rigidity			
subjects affected / exposed	0 / 130 (0.00%)	0 / 132 (0.00%)	1 / 129 (0.78%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coma			

subjects affected / exposed	0 / 130 (0.00%)	0 / 132 (0.00%)	1 / 129 (0.78%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	1 / 1
Dementia with Lewy bodies			
subjects affected / exposed	0 / 130 (0.00%)	0 / 132 (0.00%)	1 / 129 (0.78%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dizziness			
subjects affected / exposed	0 / 130 (0.00%)	1 / 132 (0.76%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhagic stroke			
subjects affected / exposed	0 / 130 (0.00%)	1 / 132 (0.76%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ischaemic stroke			
subjects affected / exposed	1 / 130 (0.77%)	1 / 132 (0.76%)	1 / 129 (0.78%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Loss of consciousness			
subjects affected / exposed	0 / 130 (0.00%)	0 / 132 (0.00%)	1 / 129 (0.78%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Sciatica			
subjects affected / exposed	0 / 130 (0.00%)	1 / 132 (0.76%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subdural hygroma			
subjects affected / exposed	0 / 130 (0.00%)	0 / 132 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Syncope			

subjects affected / exposed	0 / 130 (0.00%)	0 / 132 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subarachnoid haemorrhage alternative dictionary used: MedDRA 19			
subjects affected / exposed	0 / 130 (0.00%)	0 / 132 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Haemorrhagic anaemia			
subjects affected / exposed	1 / 130 (0.77%)	0 / 132 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombocytopenia			
subjects affected / exposed	0 / 130 (0.00%)	0 / 132 (0.00%)	1 / 129 (0.78%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			
Macular degeneration			
subjects affected / exposed	1 / 130 (0.77%)	0 / 132 (0.00%)	1 / 129 (0.78%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal discomfort			
subjects affected / exposed	0 / 130 (0.00%)	1 / 132 (0.76%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis			
subjects affected / exposed	0 / 130 (0.00%)	0 / 132 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Constipation			

subjects affected / exposed	0 / 130 (0.00%)	0 / 132 (0.00%)	1 / 129 (0.78%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Duodenal ulcer haemorrhage			
subjects affected / exposed	1 / 130 (0.77%)	1 / 132 (0.76%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dysphagia			
subjects affected / exposed	0 / 130 (0.00%)	0 / 132 (0.00%)	1 / 129 (0.78%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Faecaloma			
subjects affected / exposed	0 / 130 (0.00%)	1 / 132 (0.76%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastritis erosive			
subjects affected / exposed	0 / 130 (0.00%)	2 / 132 (1.52%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal haemorrhage			
subjects affected / exposed	0 / 130 (0.00%)	0 / 132 (0.00%)	1 / 129 (0.78%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhoidal haemorrhage			
subjects affected / exposed	1 / 130 (0.77%)	0 / 132 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Inguinal hernia			
subjects affected / exposed	1 / 130 (0.77%)	0 / 132 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Large intestine polyp			

subjects affected / exposed	1 / 130 (0.77%)	0 / 132 (0.00%)	1 / 129 (0.78%)
occurrences causally related to treatment / all	0 / 1	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Melaena			
subjects affected / exposed	0 / 130 (0.00%)	1 / 132 (0.76%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	0 / 130 (0.00%)	1 / 132 (0.76%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal failure			
subjects affected / exposed	0 / 130 (0.00%)	1 / 132 (0.76%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Lumbar spinal stenosis			
subjects affected / exposed	0 / 130 (0.00%)	0 / 132 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteoarthritis			
subjects affected / exposed	1 / 130 (0.77%)	0 / 132 (0.00%)	1 / 129 (0.78%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pain in extremity			
subjects affected / exposed	0 / 130 (0.00%)	1 / 132 (0.76%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Diverticulitis			
subjects affected / exposed	0 / 130 (0.00%)	1 / 132 (0.76%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Mastoiditis			
subjects affected / exposed	1 / 130 (0.77%)	0 / 132 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Otitis media			
subjects affected / exposed	1 / 130 (0.77%)	0 / 132 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	0 / 130 (0.00%)	0 / 132 (0.00%)	2 / 129 (1.55%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Postoperative wound infection			
subjects affected / exposed	1 / 130 (0.77%)	0 / 132 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis			
subjects affected / exposed	0 / 130 (0.00%)	0 / 132 (0.00%)	1 / 129 (0.78%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory tract infection			
subjects affected / exposed	0 / 130 (0.00%)	0 / 132 (0.00%)	1 / 129 (0.78%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	0 / 130 (0.00%)	1 / 132 (0.76%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Septic shock			
subjects affected / exposed	0 / 130 (0.00%)	0 / 132 (0.00%)	1 / 129 (0.78%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			

subjects affected / exposed	1 / 130 (0.77%)	0 / 132 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wound infection staphylococcal			
subjects affected / exposed	1 / 130 (0.77%)	0 / 132 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	1 / 130 (0.77%)	1 / 132 (0.76%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperkalaemia			
subjects affected / exposed	2 / 130 (1.54%)	0 / 132 (0.00%)	0 / 129 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 1.5 %

Non-serious adverse events	S 47445 5 mg - W0-W24	S 47445 15 mg - W0-W24	S 47445 50 mg - W0-W24
Total subjects affected by non-serious adverse events			
subjects affected / exposed	59 / 129 (45.74%)	49 / 130 (37.69%)	66 / 132 (50.00%)
Vascular disorders			
Hypertension			
subjects affected / exposed	2 / 129 (1.55%)	2 / 130 (1.54%)	1 / 132 (0.76%)
occurrences (all)	2	2	1
Orthostatic hypotension			
subjects affected / exposed	1 / 129 (0.78%)	3 / 130 (2.31%)	0 / 132 (0.00%)
occurrences (all)	1	3	0
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	0 / 129 (0.00%)	0 / 130 (0.00%)	0 / 132 (0.00%)
occurrences (all)	0	0	0
Fatigue			

subjects affected / exposed occurrences (all)	0 / 129 (0.00%) 0	0 / 130 (0.00%) 0	0 / 132 (0.00%) 0
Oedema peripheral subjects affected / exposed occurrences (all)	1 / 129 (0.78%) 1	1 / 130 (0.77%) 1	0 / 132 (0.00%) 0
Pyrexia subjects affected / exposed occurrences (all)	1 / 129 (0.78%) 1	0 / 130 (0.00%) 0	0 / 132 (0.00%) 0
Psychiatric disorders			
Aggression subjects affected / exposed occurrences (all)	0 / 129 (0.00%) 0	0 / 130 (0.00%) 0	0 / 132 (0.00%) 0
Anxiety subjects affected / exposed occurrences (all)	0 / 129 (0.00%) 0	1 / 130 (0.77%) 1	0 / 132 (0.00%) 0
Confusional state subjects affected / exposed occurrences (all)	1 / 129 (0.78%) 1	0 / 130 (0.00%) 0	0 / 132 (0.00%) 0
Delusion subjects affected / exposed occurrences (all)	0 / 129 (0.00%) 0	0 / 130 (0.00%) 0	2 / 132 (1.52%) 2
Depression subjects affected / exposed occurrences (all)	0 / 129 (0.00%) 0	0 / 130 (0.00%) 0	1 / 132 (0.76%) 1
Initial insomnia subjects affected / exposed occurrences (all)	2 / 129 (1.55%) 2	0 / 130 (0.00%) 0	0 / 132 (0.00%) 0
Insomnia subjects affected / exposed occurrences (all)	1 / 129 (0.78%) 1	2 / 130 (1.54%) 2	1 / 132 (0.76%) 1
Irritability subjects affected / exposed occurrences (all)	1 / 129 (0.78%) 1	1 / 130 (0.77%) 1	0 / 132 (0.00%) 0
Mood altered subjects affected / exposed occurrences (all)	1 / 129 (0.78%) 1	0 / 130 (0.00%) 0	0 / 132 (0.00%) 0

Nightmare subjects affected / exposed occurrences (all)	0 / 129 (0.00%) 0	0 / 130 (0.00%) 0	0 / 132 (0.00%) 0
Suicidal ideation subjects affected / exposed occurrences (all)	0 / 129 (0.00%) 0	2 / 130 (1.54%) 2	1 / 132 (0.76%) 1
Investigations			
Alanine aminotransferase increased subjects affected / exposed occurrences (all)	0 / 129 (0.00%) 0	0 / 130 (0.00%) 0	0 / 132 (0.00%) 0
Aspartate aminotransferase increased subjects affected / exposed occurrences (all)	0 / 129 (0.00%) 0	0 / 130 (0.00%) 0	0 / 132 (0.00%) 0
Blood creatine phosphokinase increased subjects affected / exposed occurrences (all)	2 / 129 (1.55%) 2	1 / 130 (0.77%) 1	6 / 132 (4.55%) 7
Blood lactate dehydrogenase increased subjects affected / exposed occurrences (all)	0 / 129 (0.00%) 0	1 / 130 (0.77%) 1	1 / 132 (0.76%) 1
Blood pressure increased subjects affected / exposed occurrences (all)	1 / 129 (0.78%) 1	2 / 130 (1.54%) 3	1 / 132 (0.76%) 2
Gamma-glutamyltransferase increased subjects affected / exposed occurrences (all)	2 / 129 (1.55%) 2	2 / 130 (1.54%) 2	1 / 132 (0.76%) 1
Weight decreased subjects affected / exposed occurrences (all)	0 / 129 (0.00%) 0	3 / 130 (2.31%) 3	2 / 132 (1.52%) 2
Injury, poisoning and procedural complications			
Accidental overdose subjects affected / exposed occurrences (all)	3 / 129 (2.33%) 3	1 / 130 (0.77%) 4	3 / 132 (2.27%) 3
Concussion			

subjects affected / exposed	1 / 129 (0.78%)	0 / 130 (0.00%)	0 / 132 (0.00%)
occurrences (all)	1	0	0
Contusion			
subjects affected / exposed	0 / 129 (0.00%)	2 / 130 (1.54%)	1 / 132 (0.76%)
occurrences (all)	0	2	1
Fall			
subjects affected / exposed	2 / 129 (1.55%)	3 / 130 (2.31%)	3 / 132 (2.27%)
occurrences (all)	2	3	3
Ligament sprain			
subjects affected / exposed	2 / 129 (1.55%)	0 / 130 (0.00%)	0 / 132 (0.00%)
occurrences (all)	2	0	0
Limb injury			
subjects affected / exposed	0 / 129 (0.00%)	0 / 130 (0.00%)	1 / 132 (0.76%)
occurrences (all)	0	0	1
Procedural pain			
subjects affected / exposed	0 / 129 (0.00%)	2 / 130 (1.54%)	0 / 132 (0.00%)
occurrences (all)	0	2	0
Traumatic haematoma			
subjects affected / exposed	0 / 129 (0.00%)	0 / 130 (0.00%)	1 / 132 (0.76%)
occurrences (all)	0	0	1
Cardiac disorders			
Atrioventricular block first degree			
subjects affected / exposed	0 / 129 (0.00%)	1 / 130 (0.77%)	0 / 132 (0.00%)
occurrences (all)	0	1	0
Bundle branch block left			
subjects affected / exposed	0 / 129 (0.00%)	0 / 130 (0.00%)	0 / 132 (0.00%)
occurrences (all)	0	0	0
Bundle branch block right			
subjects affected / exposed	0 / 129 (0.00%)	0 / 130 (0.00%)	0 / 132 (0.00%)
occurrences (all)	0	0	0
Sinus bradycardia			
subjects affected / exposed	0 / 129 (0.00%)	0 / 130 (0.00%)	2 / 132 (1.52%)
occurrences (all)	0	0	2
Sinus tachycardia			
subjects affected / exposed	0 / 129 (0.00%)	0 / 130 (0.00%)	0 / 132 (0.00%)
occurrences (all)	0	0	0

Ventricular extrasystoles subjects affected / exposed occurrences (all)	1 / 129 (0.78%) 1	0 / 130 (0.00%) 0	0 / 132 (0.00%) 0
Nervous system disorders			
Amnesia subjects affected / exposed occurrences (all)	0 / 129 (0.00%) 0	0 / 130 (0.00%) 0	0 / 132 (0.00%) 0
Dementia Alzheimer's type subjects affected / exposed occurrences (all)	2 / 129 (1.55%) 2	0 / 130 (0.00%) 0	2 / 132 (1.52%) 2
Dizziness subjects affected / exposed occurrences (all)	1 / 129 (0.78%) 1	2 / 130 (1.54%) 2	2 / 132 (1.52%) 2
Dizziness exertional subjects affected / exposed occurrences (all)	1 / 129 (0.78%) 1	2 / 130 (1.54%) 2	0 / 132 (0.00%) 0
Dizziness postural subjects affected / exposed occurrences (all)	2 / 129 (1.55%) 2	1 / 130 (0.77%) 1	1 / 132 (0.76%) 1
Headache subjects affected / exposed occurrences (all)	3 / 129 (2.33%) 4	4 / 130 (3.08%) 4	4 / 132 (3.03%) 4
Tension headache subjects affected / exposed occurrences (all)	0 / 129 (0.00%) 0	3 / 130 (2.31%) 3	0 / 132 (0.00%) 0
Blood and lymphatic system disorders			
Iron deficiency anaemia subjects affected / exposed occurrences (all)	1 / 129 (0.78%) 1	0 / 130 (0.00%) 0	1 / 132 (0.76%) 1
Leukopenia subjects affected / exposed occurrences (all)	1 / 129 (0.78%) 1	1 / 130 (0.77%) 1	3 / 132 (2.27%) 3
Normochromic normocytic anaemia subjects affected / exposed occurrences (all)	0 / 129 (0.00%) 0	1 / 130 (0.77%) 1	0 / 132 (0.00%) 0
Ear and labyrinth disorders			

Tinnitus			
subjects affected / exposed	1 / 129 (0.78%)	0 / 130 (0.00%)	0 / 132 (0.00%)
occurrences (all)	1	0	0
Vertigo positional			
subjects affected / exposed	0 / 129 (0.00%)	0 / 130 (0.00%)	2 / 132 (1.52%)
occurrences (all)	0	0	2
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	2 / 129 (1.55%)	0 / 130 (0.00%)	0 / 132 (0.00%)
occurrences (all)	2	0	0
Abdominal pain upper			
subjects affected / exposed	2 / 129 (1.55%)	1 / 130 (0.77%)	4 / 132 (3.03%)
occurrences (all)	3	1	4
Constipation			
subjects affected / exposed	3 / 129 (2.33%)	0 / 130 (0.00%)	0 / 132 (0.00%)
occurrences (all)	3	0	0
Diarrhoea			
subjects affected / exposed	1 / 129 (0.78%)	2 / 130 (1.54%)	1 / 132 (0.76%)
occurrences (all)	1	2	1
Diverticulum intestinal			
subjects affected / exposed	0 / 129 (0.00%)	0 / 130 (0.00%)	0 / 132 (0.00%)
occurrences (all)	0	0	0
Dry mouth			
subjects affected / exposed	0 / 129 (0.00%)	0 / 130 (0.00%)	2 / 132 (1.52%)
occurrences (all)	0	0	2
Gastritis			
subjects affected / exposed	1 / 129 (0.78%)	1 / 130 (0.77%)	0 / 132 (0.00%)
occurrences (all)	1	1	0
Nausea			
subjects affected / exposed	3 / 129 (2.33%)	2 / 130 (1.54%)	1 / 132 (0.76%)
occurrences (all)	3	2	1
Vomiting			
subjects affected / exposed	1 / 129 (0.78%)	0 / 130 (0.00%)	0 / 132 (0.00%)
occurrences (all)	1	0	0
Hepatobiliary disorders			

Cholelithiasis subjects affected / exposed occurrences (all)	0 / 129 (0.00%) 0	1 / 130 (0.77%) 1	0 / 132 (0.00%) 0
Hepatic steatosis subjects affected / exposed occurrences (all)	0 / 129 (0.00%) 0	0 / 130 (0.00%) 0	2 / 132 (1.52%) 2
Renal and urinary disorders Urinary incontinence subjects affected / exposed occurrences (all)	2 / 129 (1.55%) 2	0 / 130 (0.00%) 0	1 / 132 (0.76%) 1
Musculoskeletal and connective tissue disorders Arthralgia subjects affected / exposed occurrences (all)	0 / 129 (0.00%) 0	0 / 130 (0.00%) 0	1 / 132 (0.76%) 1
Musculoskeletal stiffness subjects affected / exposed occurrences (all)	1 / 129 (0.78%) 1	0 / 130 (0.00%) 0	0 / 132 (0.00%) 0
Osteoarthritis subjects affected / exposed occurrences (all)	1 / 129 (0.78%) 1	0 / 130 (0.00%) 0	1 / 132 (0.76%) 1
Infections and infestations Bronchitis subjects affected / exposed occurrences (all)	0 / 129 (0.00%) 0	2 / 130 (1.54%) 2	2 / 132 (1.52%) 2
Bronchitis bacterial subjects affected / exposed occurrences (all)	0 / 129 (0.00%) 0	0 / 130 (0.00%) 0	0 / 132 (0.00%) 0
Bronchitis viral subjects affected / exposed occurrences (all)	0 / 129 (0.00%) 0	0 / 130 (0.00%) 0	2 / 132 (1.52%) 3
Cystitis subjects affected / exposed occurrences (all)	0 / 129 (0.00%) 0	2 / 130 (1.54%) 2	1 / 132 (0.76%) 1
Gastroenteritis subjects affected / exposed occurrences (all)	0 / 129 (0.00%) 0	0 / 130 (0.00%) 0	0 / 132 (0.00%) 0

Influenza			
subjects affected / exposed	1 / 129 (0.78%)	0 / 130 (0.00%)	1 / 132 (0.76%)
occurrences (all)	1	0	1
Nasopharyngitis			
subjects affected / exposed	4 / 129 (3.10%)	3 / 130 (2.31%)	7 / 132 (5.30%)
occurrences (all)	4	3	9
Periodontitis			
subjects affected / exposed	0 / 129 (0.00%)	0 / 130 (0.00%)	0 / 132 (0.00%)
occurrences (all)	0	0	0
Rhinitis			
subjects affected / exposed	3 / 129 (2.33%)	0 / 130 (0.00%)	1 / 132 (0.76%)
occurrences (all)	3	0	1
Urinary tract infection			
subjects affected / exposed	3 / 129 (2.33%)	0 / 130 (0.00%)	1 / 132 (0.76%)
occurrences (all)	4	0	1
Viral upper respiratory tract infection			
subjects affected / exposed	0 / 129 (0.00%)	0 / 130 (0.00%)	0 / 132 (0.00%)
occurrences (all)	0	0	0
Metabolism and nutrition disorders			
Acquired mixed hyperlipidaemia			
subjects affected / exposed	0 / 129 (0.00%)	1 / 130 (0.77%)	1 / 132 (0.76%)
occurrences (all)	0	1	1
Decreased appetite			
subjects affected / exposed	1 / 129 (0.78%)	2 / 130 (1.54%)	1 / 132 (0.76%)
occurrences (all)	1	2	1
Dyslipidaemia			
subjects affected / exposed	0 / 129 (0.00%)	1 / 130 (0.77%)	0 / 132 (0.00%)
occurrences (all)	0	1	0
Glucose tolerance impaired			
subjects affected / exposed	0 / 129 (0.00%)	0 / 130 (0.00%)	1 / 132 (0.76%)
occurrences (all)	0	0	1
Hypercholesterolaemia			
subjects affected / exposed	1 / 129 (0.78%)	1 / 130 (0.77%)	0 / 132 (0.00%)
occurrences (all)	1	1	0
Hyperglycaemia			

subjects affected / exposed	1 / 129 (0.78%)	3 / 130 (2.31%)	2 / 132 (1.52%)
occurrences (all)	1	3	2
Hypertriglyceridaemia			
subjects affected / exposed	3 / 129 (2.33%)	0 / 130 (0.00%)	1 / 132 (0.76%)
occurrences (all)	3	0	1
Hyperuricaemia			
subjects affected / exposed	0 / 129 (0.00%)	0 / 130 (0.00%)	0 / 132 (0.00%)
occurrences (all)	0	0	0
Hypoglycaemia			
subjects affected / exposed	1 / 129 (0.78%)	0 / 130 (0.00%)	0 / 132 (0.00%)
occurrences (all)	1	0	0
Hypokalaemia			
subjects affected / exposed	0 / 129 (0.00%)	2 / 130 (1.54%)	1 / 132 (0.76%)
occurrences (all)	0	2	1
Hyponatraemia			
subjects affected / exposed	0 / 129 (0.00%)	0 / 130 (0.00%)	0 / 132 (0.00%)
occurrences (all)	0	0	0
Malnutrition			
subjects affected / exposed	0 / 129 (0.00%)	1 / 130 (0.77%)	1 / 132 (0.76%)
occurrences (all)	0	1	1
Type 2 diabetes mellitus			
subjects affected / exposed	4 / 129 (3.10%)	1 / 130 (0.77%)	1 / 132 (0.76%)
occurrences (all)	4	1	1

Non-serious adverse events	Placebo - W0-W24	S 47445 5 mg - W24-W52	S 47445 15 mg - W24-W52
Total subjects affected by non-serious adverse events			
subjects affected / exposed	60 / 129 (46.51%)	50 / 119 (42.02%)	42 / 115 (36.52%)
Vascular disorders			
Hypertension			
subjects affected / exposed	3 / 129 (2.33%)	2 / 119 (1.68%)	2 / 115 (1.74%)
occurrences (all)	3	2	2
Orthostatic hypotension			
subjects affected / exposed	0 / 129 (0.00%)	0 / 119 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
General disorders and administration site conditions			

Asthenia			
subjects affected / exposed	1 / 129 (0.78%)	3 / 119 (2.52%)	2 / 115 (1.74%)
occurrences (all)	1	3	2
Fatigue			
subjects affected / exposed	2 / 129 (1.55%)	0 / 119 (0.00%)	1 / 115 (0.87%)
occurrences (all)	2	0	1
Oedema peripheral			
subjects affected / exposed	0 / 129 (0.00%)	1 / 119 (0.84%)	1 / 115 (0.87%)
occurrences (all)	0	1	1
Pyrexia			
subjects affected / exposed	0 / 129 (0.00%)	1 / 119 (0.84%)	1 / 115 (0.87%)
occurrences (all)	0	1	1
Psychiatric disorders			
Aggression			
subjects affected / exposed	1 / 129 (0.78%)	0 / 119 (0.00%)	0 / 115 (0.00%)
occurrences (all)	1	0	0
Anxiety			
subjects affected / exposed	1 / 129 (0.78%)	0 / 119 (0.00%)	1 / 115 (0.87%)
occurrences (all)	1	0	1
Confusional state			
subjects affected / exposed	2 / 129 (1.55%)	0 / 119 (0.00%)	0 / 115 (0.00%)
occurrences (all)	3	0	0
Delusion			
subjects affected / exposed	0 / 129 (0.00%)	0 / 119 (0.00%)	0 / 115 (0.00%)
occurrences (all)	0	0	0
Depression			
subjects affected / exposed	2 / 129 (1.55%)	0 / 119 (0.00%)	1 / 115 (0.87%)
occurrences (all)	2	0	1
Initial insomnia			
subjects affected / exposed	2 / 129 (1.55%)	0 / 119 (0.00%)	0 / 115 (0.00%)
occurrences (all)	2	0	0
Insomnia			
subjects affected / exposed	1 / 129 (0.78%)	1 / 119 (0.84%)	0 / 115 (0.00%)
occurrences (all)	1	1	0
Irritability			

subjects affected / exposed	2 / 129 (1.55%)	1 / 119 (0.84%)	1 / 115 (0.87%)
occurrences (all)	2	1	1
Mood altered			
subjects affected / exposed	0 / 129 (0.00%)	1 / 119 (0.84%)	0 / 115 (0.00%)
occurrences (all)	0	1	0
Nightmare			
subjects affected / exposed	1 / 129 (0.78%)	2 / 119 (1.68%)	0 / 115 (0.00%)
occurrences (all)	1	2	0
Suicidal ideation			
subjects affected / exposed	1 / 129 (0.78%)	0 / 119 (0.00%)	0 / 115 (0.00%)
occurrences (all)	1	0	0
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	0 / 129 (0.00%)	2 / 119 (1.68%)	0 / 115 (0.00%)
occurrences (all)	0	2	0
Aspartate aminotransferase increased			
subjects affected / exposed	0 / 129 (0.00%)	2 / 119 (1.68%)	0 / 115 (0.00%)
occurrences (all)	0	2	0
Blood creatine phosphokinase increased			
subjects affected / exposed	4 / 129 (3.10%)	5 / 119 (4.20%)	1 / 115 (0.87%)
occurrences (all)	4	5	1
Blood lactate dehydrogenase increased			
subjects affected / exposed	2 / 129 (1.55%)	0 / 119 (0.00%)	0 / 115 (0.00%)
occurrences (all)	2	0	0
Blood pressure increased			
subjects affected / exposed	1 / 129 (0.78%)	0 / 119 (0.00%)	1 / 115 (0.87%)
occurrences (all)	1	0	1
Gamma-glutamyltransferase increased			
subjects affected / exposed	1 / 129 (0.78%)	2 / 119 (1.68%)	1 / 115 (0.87%)
occurrences (all)	1	2	1
Weight decreased			
subjects affected / exposed	2 / 129 (1.55%)	1 / 119 (0.84%)	1 / 115 (0.87%)
occurrences (all)	2	1	1
Injury, poisoning and procedural complications			

Accidental overdose subjects affected / exposed occurrences (all)	1 / 129 (0.78%) 1	0 / 119 (0.00%) 0	2 / 115 (1.74%) 2
Concussion subjects affected / exposed occurrences (all)	0 / 129 (0.00%) 0	0 / 119 (0.00%) 0	2 / 115 (1.74%) 2
Contusion subjects affected / exposed occurrences (all)	0 / 129 (0.00%) 0	0 / 119 (0.00%) 0	1 / 115 (0.87%) 1
Fall subjects affected / exposed occurrences (all)	2 / 129 (1.55%) 2	1 / 119 (0.84%) 1	1 / 115 (0.87%) 1
Ligament sprain subjects affected / exposed occurrences (all)	0 / 129 (0.00%) 0	0 / 119 (0.00%) 0	0 / 115 (0.00%) 0
Limb injury subjects affected / exposed occurrences (all)	1 / 129 (0.78%) 1	0 / 119 (0.00%) 0	0 / 115 (0.00%) 0
Procedural pain subjects affected / exposed occurrences (all)	0 / 129 (0.00%) 0	0 / 119 (0.00%) 0	0 / 115 (0.00%) 0
Traumatic haematoma subjects affected / exposed occurrences (all)	1 / 129 (0.78%) 1	0 / 119 (0.00%) 0	1 / 115 (0.87%) 1
Cardiac disorders			
Atrioventricular block first degree subjects affected / exposed occurrences (all)	0 / 129 (0.00%) 0	2 / 119 (1.68%) 2	0 / 115 (0.00%) 0
Bundle branch block left subjects affected / exposed occurrences (all)	3 / 129 (2.33%) 3	0 / 119 (0.00%) 0	0 / 115 (0.00%) 0
Bundle branch block right subjects affected / exposed occurrences (all)	2 / 129 (1.55%) 2	0 / 119 (0.00%) 0	1 / 115 (0.87%) 1
Sinus bradycardia			

subjects affected / exposed	1 / 129 (0.78%)	0 / 119 (0.00%)	0 / 115 (0.00%)
occurrences (all)	1	0	0
Sinus tachycardia			
subjects affected / exposed	2 / 129 (1.55%)	0 / 119 (0.00%)	0 / 115 (0.00%)
occurrences (all)	2	0	0
Ventricular extrasystoles			
subjects affected / exposed	1 / 129 (0.78%)	0 / 119 (0.00%)	0 / 115 (0.00%)
occurrences (all)	1	0	0
Nervous system disorders			
Amnesia			
subjects affected / exposed	0 / 129 (0.00%)	2 / 119 (1.68%)	0 / 115 (0.00%)
occurrences (all)	0	2	0
Dementia Alzheimer's type			
subjects affected / exposed	0 / 129 (0.00%)	0 / 119 (0.00%)	0 / 115 (0.00%)
occurrences (all)	0	0	0
Dizziness			
subjects affected / exposed	0 / 129 (0.00%)	0 / 119 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
Dizziness exertional			
subjects affected / exposed	0 / 129 (0.00%)	0 / 119 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
Dizziness postural			
subjects affected / exposed	2 / 129 (1.55%)	4 / 119 (3.36%)	1 / 115 (0.87%)
occurrences (all)	2	6	1
Headache			
subjects affected / exposed	5 / 129 (3.88%)	5 / 119 (4.20%)	3 / 115 (2.61%)
occurrences (all)	5	5	3
Tension headache			
subjects affected / exposed	3 / 129 (2.33%)	0 / 119 (0.00%)	0 / 115 (0.00%)
occurrences (all)	3	0	0
Blood and lymphatic system disorders			
Iron deficiency anaemia			
subjects affected / exposed	0 / 129 (0.00%)	0 / 119 (0.00%)	2 / 115 (1.74%)
occurrences (all)	0	0	2
Leukopenia			

subjects affected / exposed	0 / 129 (0.00%)	0 / 119 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
Normochromic normocytic anaemia			
subjects affected / exposed	0 / 129 (0.00%)	0 / 119 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
Ear and labyrinth disorders			
Tinnitus			
subjects affected / exposed	0 / 129 (0.00%)	1 / 119 (0.84%)	0 / 115 (0.00%)
occurrences (all)	0	1	0
Vertigo positional			
subjects affected / exposed	0 / 129 (0.00%)	0 / 119 (0.00%)	0 / 115 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	0 / 129 (0.00%)	1 / 119 (0.84%)	0 / 115 (0.00%)
occurrences (all)	0	1	0
Abdominal pain upper			
subjects affected / exposed	0 / 129 (0.00%)	0 / 119 (0.00%)	0 / 115 (0.00%)
occurrences (all)	0	0	0
Constipation			
subjects affected / exposed	0 / 129 (0.00%)	0 / 119 (0.00%)	0 / 115 (0.00%)
occurrences (all)	0	0	0
Diarrhoea			
subjects affected / exposed	4 / 129 (3.10%)	5 / 119 (4.20%)	6 / 115 (5.22%)
occurrences (all)	4	5	6
Diverticulum intestinal			
subjects affected / exposed	0 / 129 (0.00%)	0 / 119 (0.00%)	0 / 115 (0.00%)
occurrences (all)	0	0	0
Dry mouth			
subjects affected / exposed	0 / 129 (0.00%)	1 / 119 (0.84%)	0 / 115 (0.00%)
occurrences (all)	0	1	0
Gastritis			
subjects affected / exposed	1 / 129 (0.78%)	0 / 119 (0.00%)	0 / 115 (0.00%)
occurrences (all)	1	0	0
Nausea			

subjects affected / exposed	1 / 129 (0.78%)	5 / 119 (4.20%)	6 / 115 (5.22%)
occurrences (all)	1	9	6
Vomiting			
subjects affected / exposed	0 / 129 (0.00%)	2 / 119 (1.68%)	2 / 115 (1.74%)
occurrences (all)	0	2	2
Hepatobiliary disorders			
Cholelithiasis			
subjects affected / exposed	0 / 129 (0.00%)	0 / 119 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
Hepatic steatosis			
subjects affected / exposed	1 / 129 (0.78%)	0 / 119 (0.00%)	0 / 115 (0.00%)
occurrences (all)	1	0	0
Renal and urinary disorders			
Urinary incontinence			
subjects affected / exposed	1 / 129 (0.78%)	1 / 119 (0.84%)	1 / 115 (0.87%)
occurrences (all)	1	1	1
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	0 / 129 (0.00%)	1 / 119 (0.84%)	4 / 115 (3.48%)
occurrences (all)	0	1	4
Musculoskeletal stiffness			
subjects affected / exposed	0 / 129 (0.00%)	1 / 119 (0.84%)	0 / 115 (0.00%)
occurrences (all)	0	1	0
Osteoarthritis			
subjects affected / exposed	0 / 129 (0.00%)	0 / 119 (0.00%)	0 / 115 (0.00%)
occurrences (all)	0	0	0
Infections and infestations			
Bronchitis			
subjects affected / exposed	1 / 129 (0.78%)	0 / 119 (0.00%)	0 / 115 (0.00%)
occurrences (all)	1	0	0
Bronchitis bacterial			
subjects affected / exposed	2 / 129 (1.55%)	0 / 119 (0.00%)	0 / 115 (0.00%)
occurrences (all)	2	0	0
Bronchitis viral			
subjects affected / exposed	0 / 129 (0.00%)	0 / 119 (0.00%)	0 / 115 (0.00%)
occurrences (all)	0	0	0

Cystitis			
subjects affected / exposed	0 / 129 (0.00%)	0 / 119 (0.00%)	0 / 115 (0.00%)
occurrences (all)	0	0	0
Gastroenteritis			
subjects affected / exposed	1 / 129 (0.78%)	0 / 119 (0.00%)	0 / 115 (0.00%)
occurrences (all)	1	0	0
Influenza			
subjects affected / exposed	2 / 129 (1.55%)	1 / 119 (0.84%)	1 / 115 (0.87%)
occurrences (all)	2	1	1
Nasopharyngitis			
subjects affected / exposed	6 / 129 (4.65%)	0 / 119 (0.00%)	0 / 115 (0.00%)
occurrences (all)	7	0	0
Periodontitis			
subjects affected / exposed	0 / 129 (0.00%)	1 / 119 (0.84%)	2 / 115 (1.74%)
occurrences (all)	0	1	2
Rhinitis			
subjects affected / exposed	1 / 129 (0.78%)	0 / 119 (0.00%)	0 / 115 (0.00%)
occurrences (all)	1	0	0
Urinary tract infection			
subjects affected / exposed	6 / 129 (4.65%)	2 / 119 (1.68%)	0 / 115 (0.00%)
occurrences (all)	8	3	0
Viral upper respiratory tract infection			
subjects affected / exposed	0 / 129 (0.00%)	6 / 119 (5.04%)	2 / 115 (1.74%)
occurrences (all)	0	6	2
Metabolism and nutrition disorders			
Acquired mixed hyperlipidaemia			
subjects affected / exposed	1 / 129 (0.78%)	0 / 119 (0.00%)	0 / 115 (0.00%)
occurrences (all)	1	0	0
Decreased appetite			
subjects affected / exposed	0 / 129 (0.00%)	1 / 119 (0.84%)	4 / 115 (3.48%)
occurrences (all)	0	1	4
Dyslipidaemia			
subjects affected / exposed	0 / 129 (0.00%)	0 / 119 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
Glucose tolerance impaired			

subjects affected / exposed	0 / 129 (0.00%)	0 / 119 (0.00%)	0 / 115 (0.00%)
occurrences (all)	0	0	0
Hypercholesterolaemia			
subjects affected / exposed	1 / 129 (0.78%)	2 / 119 (1.68%)	3 / 115 (2.61%)
occurrences (all)	1	2	3
Hyperglycaemia			
subjects affected / exposed	0 / 129 (0.00%)	1 / 119 (0.84%)	1 / 115 (0.87%)
occurrences (all)	0	1	1
Hypertriglyceridaemia			
subjects affected / exposed	2 / 129 (1.55%)	2 / 119 (1.68%)	0 / 115 (0.00%)
occurrences (all)	2	3	0
Hyperuricaemia			
subjects affected / exposed	1 / 129 (0.78%)	0 / 119 (0.00%)	2 / 115 (1.74%)
occurrences (all)	1	0	2
Hypoglycaemia			
subjects affected / exposed	0 / 129 (0.00%)	1 / 119 (0.84%)	0 / 115 (0.00%)
occurrences (all)	0	2	0
Hypokalaemia			
subjects affected / exposed	0 / 129 (0.00%)	0 / 119 (0.00%)	0 / 115 (0.00%)
occurrences (all)	0	0	0
Hyponatraemia			
subjects affected / exposed	1 / 129 (0.78%)	0 / 119 (0.00%)	2 / 115 (1.74%)
occurrences (all)	1	0	2
Malnutrition			
subjects affected / exposed	0 / 129 (0.00%)	0 / 119 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
Type 2 diabetes mellitus			
subjects affected / exposed	1 / 129 (0.78%)	0 / 119 (0.00%)	0 / 115 (0.00%)
occurrences (all)	1	0	0

Non-serious adverse events	S 47445 50 mg - W24-W52	Placebo - W24-W52	S 47445 5 mg - W0-W52
Total subjects affected by non-serious adverse events			
subjects affected / exposed	41 / 115 (35.65%)	41 / 119 (34.45%)	78 / 129 (60.47%)
Vascular disorders			
Hypertension			

subjects affected / exposed occurrences (all)	2 / 115 (1.74%) 2	3 / 119 (2.52%) 3	5 / 129 (3.88%) 5
Orthostatic hypotension subjects affected / exposed occurrences (all)	1 / 115 (0.87%) 1	0 / 119 (0.00%) 0	1 / 129 (0.78%) 1
General disorders and administration site conditions			
Asthenia subjects affected / exposed occurrences (all)	1 / 115 (0.87%) 1	0 / 119 (0.00%) 0	3 / 129 (2.33%) 3
Fatigue subjects affected / exposed occurrences (all)	1 / 115 (0.87%) 1	1 / 119 (0.84%) 1	0 / 129 (0.00%) 0
Oedema peripheral subjects affected / exposed occurrences (all)	0 / 115 (0.00%) 0	0 / 119 (0.00%) 0	2 / 129 (1.55%) 2
Pyrexia subjects affected / exposed occurrences (all)	0 / 115 (0.00%) 0	0 / 119 (0.00%) 0	2 / 129 (1.55%) 2
Psychiatric disorders			
Aggression subjects affected / exposed occurrences (all)	2 / 115 (1.74%) 2	0 / 119 (0.00%) 0	0 / 129 (0.00%) 0
Anxiety subjects affected / exposed occurrences (all)	1 / 115 (0.87%) 1	0 / 119 (0.00%) 0	0 / 129 (0.00%) 0
Confusional state subjects affected / exposed occurrences (all)	0 / 115 (0.00%) 0	0 / 119 (0.00%) 0	1 / 129 (0.78%) 1
Delusion subjects affected / exposed occurrences (all)	1 / 115 (0.87%) 1	1 / 119 (0.84%) 2	0 / 129 (0.00%) 0
Depression subjects affected / exposed occurrences (all)	1 / 115 (0.87%) 1	0 / 119 (0.00%) 0	0 / 129 (0.00%) 0
Initial insomnia			

subjects affected / exposed	0 / 115 (0.00%)	1 / 119 (0.84%)	2 / 129 (1.55%)
occurrences (all)	0	1	2
Insomnia			
subjects affected / exposed	2 / 115 (1.74%)	1 / 119 (0.84%)	2 / 129 (1.55%)
occurrences (all)	2	1	2
Irritability			
subjects affected / exposed	1 / 115 (0.87%)	0 / 119 (0.00%)	2 / 129 (1.55%)
occurrences (all)	1	0	2
Mood altered			
subjects affected / exposed	0 / 115 (0.00%)	0 / 119 (0.00%)	2 / 129 (1.55%)
occurrences (all)	0	0	2
Nightmare			
subjects affected / exposed	1 / 115 (0.87%)	1 / 119 (0.84%)	2 / 129 (1.55%)
occurrences (all)	1	1	2
Suicidal ideation			
subjects affected / exposed	0 / 115 (0.00%)	0 / 119 (0.00%)	0 / 129 (0.00%)
occurrences (all)	0	0	0
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	0 / 115 (0.00%)	0 / 119 (0.00%)	2 / 129 (1.55%)
occurrences (all)	0	0	2
Aspartate aminotransferase increased			
subjects affected / exposed	0 / 115 (0.00%)	1 / 119 (0.84%)	2 / 129 (1.55%)
occurrences (all)	0	1	2
Blood creatine phosphokinase increased			
subjects affected / exposed	0 / 115 (0.00%)	2 / 119 (1.68%)	7 / 129 (5.43%)
occurrences (all)	0	2	7
Blood lactate dehydrogenase increased			
subjects affected / exposed	0 / 115 (0.00%)	0 / 119 (0.00%)	0 / 129 (0.00%)
occurrences (all)	0	0	0
Blood pressure increased			
subjects affected / exposed	0 / 115 (0.00%)	0 / 119 (0.00%)	1 / 129 (0.78%)
occurrences (all)	0	0	1
Gamma-glutamyltransferase increased			

subjects affected / exposed occurrences (all)	0 / 115 (0.00%) 0	0 / 119 (0.00%) 0	4 / 129 (3.10%) 4
Weight decreased subjects affected / exposed occurrences (all)	1 / 115 (0.87%) 1	1 / 119 (0.84%) 1	1 / 129 (0.78%) 1
Injury, poisoning and procedural complications			
Accidental overdose subjects affected / exposed occurrences (all)	2 / 115 (1.74%) 3	2 / 119 (1.68%) 2	3 / 129 (2.33%) 3
Concussion subjects affected / exposed occurrences (all)	0 / 115 (0.00%) 0	0 / 119 (0.00%) 0	1 / 129 (0.78%) 1
Contusion subjects affected / exposed occurrences (all)	1 / 115 (0.87%) 1	0 / 119 (0.00%) 0	0 / 129 (0.00%) 0
Fall subjects affected / exposed occurrences (all)	2 / 115 (1.74%) 2	2 / 119 (1.68%) 2	3 / 129 (2.33%) 3
Ligament sprain subjects affected / exposed occurrences (all)	0 / 115 (0.00%) 0	0 / 119 (0.00%) 0	2 / 129 (1.55%) 2
Limb injury subjects affected / exposed occurrences (all)	0 / 115 (0.00%) 0	1 / 119 (0.84%) 1	0 / 129 (0.00%) 0
Procedural pain subjects affected / exposed occurrences (all)	0 / 115 (0.00%) 0	0 / 119 (0.00%) 0	0 / 129 (0.00%) 0
Traumatic haematoma subjects affected / exposed occurrences (all)	1 / 115 (0.87%) 1	1 / 119 (0.84%) 1	0 / 129 (0.00%) 0
Cardiac disorders			
Atrioventricular block first degree subjects affected / exposed occurrences (all)	0 / 115 (0.00%) 0	0 / 119 (0.00%) 0	2 / 129 (1.55%) 2
Bundle branch block left			

subjects affected / exposed	0 / 115 (0.00%)	0 / 119 (0.00%)	0 / 129 (0.00%)
occurrences (all)	0	0	0
Bundle branch block right			
subjects affected / exposed	0 / 115 (0.00%)	0 / 119 (0.00%)	0 / 129 (0.00%)
occurrences (all)	0	0	0
Sinus bradycardia			
subjects affected / exposed	1 / 115 (0.87%)	1 / 119 (0.84%)	0 / 129 (0.00%)
occurrences (all)	1	1	0
Sinus tachycardia			
subjects affected / exposed	0 / 115 (0.00%)	0 / 119 (0.00%)	0 / 129 (0.00%)
occurrences (all)	0	0	0
Ventricular extrasystoles			
subjects affected / exposed	0 / 115 (0.00%)	1 / 119 (0.84%)	1 / 129 (0.78%)
occurrences (all)	0	1	1
Nervous system disorders			
Amnesia			
subjects affected / exposed	0 / 115 (0.00%)	0 / 119 (0.00%)	2 / 129 (1.55%)
occurrences (all)	0	0	2
Dementia Alzheimer's type			
subjects affected / exposed	0 / 115 (0.00%)	0 / 119 (0.00%)	2 / 129 (1.55%)
occurrences (all)	0	0	2
Dizziness			
subjects affected / exposed	2 / 115 (1.74%)	0 / 119 (0.00%)	1 / 129 (0.78%)
occurrences (all)	2	0	1
Dizziness exertional			
subjects affected / exposed	0 / 115 (0.00%)	0 / 119 (0.00%)	1 / 129 (0.78%)
occurrences (all)	0	0	1
Dizziness postural			
subjects affected / exposed	1 / 115 (0.87%)	1 / 119 (0.84%)	5 / 129 (3.88%)
occurrences (all)	1	1	8
Headache			
subjects affected / exposed	1 / 115 (0.87%)	3 / 119 (2.52%)	7 / 129 (5.43%)
occurrences (all)	1	4	9
Tension headache			
subjects affected / exposed	0 / 115 (0.00%)	1 / 119 (0.84%)	0 / 129 (0.00%)
occurrences (all)	0	1	0

Blood and lymphatic system disorders			
Iron deficiency anaemia			
subjects affected / exposed	0 / 115 (0.00%)	0 / 119 (0.00%)	1 / 129 (0.78%)
occurrences (all)	0	0	1
Leukopenia			
subjects affected / exposed	1 / 115 (0.87%)	0 / 119 (0.00%)	1 / 129 (0.78%)
occurrences (all)	1	0	1
Normochromic normocytic anaemia			
subjects affected / exposed	0 / 115 (0.00%)	0 / 119 (0.00%)	0 / 129 (0.00%)
occurrences (all)	0	0	0
Ear and labyrinth disorders			
Tinnitus			
subjects affected / exposed	0 / 115 (0.00%)	0 / 119 (0.00%)	2 / 129 (1.55%)
occurrences (all)	0	0	2
Vertigo positional			
subjects affected / exposed	0 / 115 (0.00%)	1 / 119 (0.84%)	0 / 129 (0.00%)
occurrences (all)	0	1	0
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	1 / 115 (0.87%)	1 / 119 (0.84%)	3 / 129 (2.33%)
occurrences (all)	1	1	3
Abdominal pain upper			
subjects affected / exposed	0 / 115 (0.00%)	0 / 119 (0.00%)	2 / 129 (1.55%)
occurrences (all)	0	0	3
Constipation			
subjects affected / exposed	0 / 115 (0.00%)	0 / 119 (0.00%)	3 / 129 (2.33%)
occurrences (all)	0	0	3
Diarrhoea			
subjects affected / exposed	1 / 115 (0.87%)	2 / 119 (1.68%)	6 / 129 (4.65%)
occurrences (all)	1	2	6
Diverticulum intestinal			
subjects affected / exposed	0 / 115 (0.00%)	2 / 119 (1.68%)	0 / 129 (0.00%)
occurrences (all)	0	2	0
Dry mouth			
subjects affected / exposed	1 / 115 (0.87%)	1 / 119 (0.84%)	1 / 129 (0.78%)
occurrences (all)	1	1	1
Gastritis			

subjects affected / exposed occurrences (all)	1 / 115 (0.87%) 1	1 / 119 (0.84%) 1	1 / 129 (0.78%) 1
Nausea subjects affected / exposed occurrences (all)	3 / 115 (2.61%) 3	5 / 119 (4.20%) 5	8 / 129 (6.20%) 12
Vomiting subjects affected / exposed occurrences (all)	3 / 115 (2.61%) 3	2 / 119 (1.68%) 2	3 / 129 (2.33%) 3
Hepatobiliary disorders Cholelithiasis subjects affected / exposed occurrences (all)	0 / 115 (0.00%) 0	0 / 119 (0.00%) 0	0 / 129 (0.00%) 0
Hepatic steatosis subjects affected / exposed occurrences (all)	1 / 115 (0.87%) 1	0 / 119 (0.00%) 0	0 / 129 (0.00%) 0
Renal and urinary disorders Urinary incontinence subjects affected / exposed occurrences (all)	0 / 115 (0.00%) 0	0 / 119 (0.00%) 0	2 / 129 (1.55%) 3
Musculoskeletal and connective tissue disorders Arthralgia subjects affected / exposed occurrences (all)	0 / 115 (0.00%) 0	1 / 119 (0.84%) 1	1 / 129 (0.78%) 1
Musculoskeletal stiffness subjects affected / exposed occurrences (all)	0 / 115 (0.00%) 0	0 / 119 (0.00%) 0	2 / 129 (1.55%) 2
Osteoarthritis subjects affected / exposed occurrences (all)	0 / 115 (0.00%) 0	1 / 119 (0.84%) 2	1 / 129 (0.78%) 1
Infections and infestations Bronchitis subjects affected / exposed occurrences (all)	1 / 115 (0.87%) 1	1 / 119 (0.84%) 1	0 / 129 (0.00%) 0
Bronchitis bacterial subjects affected / exposed occurrences (all)	0 / 115 (0.00%) 0	0 / 119 (0.00%) 0	0 / 129 (0.00%) 0

Bronchitis viral subjects affected / exposed occurrences (all)	0 / 115 (0.00%) 0	0 / 119 (0.00%) 0	0 / 129 (0.00%) 0
Cystitis subjects affected / exposed occurrences (all)	0 / 115 (0.00%) 0	0 / 119 (0.00%) 0	0 / 129 (0.00%) 0
Gastroenteritis subjects affected / exposed occurrences (all)	0 / 115 (0.00%) 0	1 / 119 (0.84%) 1	0 / 129 (0.00%) 0
Influenza subjects affected / exposed occurrences (all)	0 / 115 (0.00%) 0	4 / 119 (3.36%) 4	2 / 129 (1.55%) 2
Nasopharyngitis subjects affected / exposed occurrences (all)	0 / 115 (0.00%) 0	0 / 119 (0.00%) 0	1 / 129 (0.78%) 1
Periodontitis subjects affected / exposed occurrences (all)	1 / 115 (0.87%) 1	2 / 119 (1.68%) 2	1 / 129 (0.78%) 1
Rhinitis subjects affected / exposed occurrences (all)	0 / 115 (0.00%) 0	0 / 119 (0.00%) 0	3 / 129 (2.33%) 3
Urinary tract infection subjects affected / exposed occurrences (all)	0 / 115 (0.00%) 0	1 / 119 (0.84%) 2	4 / 129 (3.10%) 7
Viral upper respiratory tract infection subjects affected / exposed occurrences (all)	3 / 115 (2.61%) 3	0 / 119 (0.00%) 0	8 / 129 (6.20%) 9
Metabolism and nutrition disorders			
Acquired mixed hyperlipidaemia subjects affected / exposed occurrences (all)	0 / 115 (0.00%) 0	1 / 119 (0.84%) 1	0 / 129 (0.00%) 0
Decreased appetite subjects affected / exposed occurrences (all)	2 / 115 (1.74%) 2	1 / 119 (0.84%) 1	2 / 129 (1.55%) 2
Dyslipidaemia			

subjects affected / exposed	0 / 115 (0.00%)	0 / 119 (0.00%)	0 / 129 (0.00%)
occurrences (all)	0	0	0
Glucose tolerance impaired			
subjects affected / exposed	1 / 115 (0.87%)	0 / 119 (0.00%)	0 / 129 (0.00%)
occurrences (all)	1	0	0
Hypercholesterolaemia			
subjects affected / exposed	2 / 115 (1.74%)	0 / 119 (0.00%)	4 / 129 (3.10%)
occurrences (all)	2	0	4
Hyperglycaemia			
subjects affected / exposed	0 / 115 (0.00%)	0 / 119 (0.00%)	2 / 129 (1.55%)
occurrences (all)	0	0	2
Hypertriglyceridaemia			
subjects affected / exposed	1 / 115 (0.87%)	1 / 119 (0.84%)	6 / 129 (4.65%)
occurrences (all)	1	1	7
Hyperuricaemia			
subjects affected / exposed	0 / 115 (0.00%)	0 / 119 (0.00%)	0 / 129 (0.00%)
occurrences (all)	0	0	0
Hypoglycaemia			
subjects affected / exposed	0 / 115 (0.00%)	0 / 119 (0.00%)	2 / 129 (1.55%)
occurrences (all)	0	0	3
Hypokalaemia			
subjects affected / exposed	0 / 115 (0.00%)	0 / 119 (0.00%)	0 / 129 (0.00%)
occurrences (all)	0	0	0
Hyponatraemia			
subjects affected / exposed	3 / 115 (2.61%)	1 / 119 (0.84%)	0 / 129 (0.00%)
occurrences (all)	3	1	0
Malnutrition			
subjects affected / exposed	1 / 115 (0.87%)	0 / 119 (0.00%)	0 / 129 (0.00%)
occurrences (all)	1	0	0
Type 2 diabetes mellitus			
subjects affected / exposed	1 / 115 (0.87%)	1 / 119 (0.84%)	4 / 129 (3.10%)
occurrences (all)	1	1	4

Non-serious adverse events	S 47445 15 mg - W0-W52	S 47445 50 mg - W0-W52	Placebo - W0-W52
Total subjects affected by non-serious adverse events			
subjects affected / exposed	70 / 130 (53.85%)	79 / 132 (59.85%)	76 / 129 (58.91%)

Vascular disorders			
Hypertension			
subjects affected / exposed	4 / 130 (3.08%)	3 / 132 (2.27%)	7 / 129 (5.43%)
occurrences (all)	4	3	7
Orthostatic hypotension			
subjects affected / exposed	4 / 130 (3.08%)	1 / 132 (0.76%)	0 / 129 (0.00%)
occurrences (all)	4	1	0
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	2 / 130 (1.54%)	1 / 132 (0.76%)	1 / 129 (0.78%)
occurrences (all)	2	1	1
Fatigue			
subjects affected / exposed	1 / 130 (0.77%)	1 / 132 (0.76%)	3 / 129 (2.33%)
occurrences (all)	1	1	3
Oedema peripheral			
subjects affected / exposed	2 / 130 (1.54%)	0 / 132 (0.00%)	0 / 129 (0.00%)
occurrences (all)	2	0	0
Pyrexia			
subjects affected / exposed	1 / 130 (0.77%)	0 / 132 (0.00%)	0 / 129 (0.00%)
occurrences (all)	1	0	0
Psychiatric disorders			
Aggression			
subjects affected / exposed	0 / 130 (0.00%)	2 / 132 (1.52%)	1 / 129 (0.78%)
occurrences (all)	0	2	1
Anxiety			
subjects affected / exposed	2 / 130 (1.54%)	1 / 132 (0.76%)	1 / 129 (0.78%)
occurrences (all)	2	1	1
Confusional state			
subjects affected / exposed	0 / 130 (0.00%)	0 / 132 (0.00%)	2 / 129 (1.55%)
occurrences (all)	0	0	3
Delusion			
subjects affected / exposed	0 / 130 (0.00%)	2 / 132 (1.52%)	1 / 129 (0.78%)
occurrences (all)	0	2	2
Depression			
subjects affected / exposed	1 / 130 (0.77%)	2 / 132 (1.52%)	2 / 129 (1.55%)
occurrences (all)	1	2	2

Initial insomnia subjects affected / exposed occurrences (all)	0 / 130 (0.00%) 0	0 / 132 (0.00%) 0	3 / 129 (2.33%) 3
Insomnia subjects affected / exposed occurrences (all)	2 / 130 (1.54%) 2	3 / 132 (2.27%) 3	2 / 129 (1.55%) 2
Irritability subjects affected / exposed occurrences (all)	2 / 130 (1.54%) 2	1 / 132 (0.76%) 1	2 / 129 (1.55%) 2
Mood altered subjects affected / exposed occurrences (all)	0 / 130 (0.00%) 0	0 / 132 (0.00%) 0	0 / 129 (0.00%) 0
Nightmare subjects affected / exposed occurrences (all)	0 / 130 (0.00%) 0	1 / 132 (0.76%) 1	2 / 129 (1.55%) 2
Suicidal ideation subjects affected / exposed occurrences (all)	2 / 130 (1.54%) 2	1 / 132 (0.76%) 1	1 / 129 (0.78%) 1
Investigations			
Alanine aminotransferase increased subjects affected / exposed occurrences (all)	0 / 130 (0.00%) 0	0 / 132 (0.00%) 0	0 / 129 (0.00%) 0
Aspartate aminotransferase increased subjects affected / exposed occurrences (all)	0 / 130 (0.00%) 0	0 / 132 (0.00%) 0	1 / 129 (0.78%) 1
Blood creatine phosphokinase increased subjects affected / exposed occurrences (all)	2 / 130 (1.54%) 2	6 / 132 (4.55%) 7	6 / 129 (4.65%) 6
Blood lactate dehydrogenase increased subjects affected / exposed occurrences (all)	1 / 130 (0.77%) 1	1 / 132 (0.76%) 1	2 / 129 (1.55%) 2
Blood pressure increased subjects affected / exposed occurrences (all)	3 / 130 (2.31%) 4	2 / 132 (1.52%) 3	1 / 129 (0.78%) 1
Gamma-glutamyltransferase			

increased subjects affected / exposed occurrences (all)	3 / 130 (2.31%) 3	1 / 132 (0.76%) 1	1 / 129 (0.78%) 1
Weight decreased subjects affected / exposed occurrences (all)	4 / 130 (3.08%) 4	2 / 132 (1.52%) 2	3 / 129 (2.33%) 3
Injury, poisoning and procedural complications			
Accidental overdose subjects affected / exposed occurrences (all)	2 / 130 (1.54%) 6	5 / 132 (3.79%) 6	3 / 129 (2.33%) 3
Concussion subjects affected / exposed occurrences (all)	2 / 130 (1.54%) 2	0 / 132 (0.00%) 0	0 / 129 (0.00%) 0
Contusion subjects affected / exposed occurrences (all)	3 / 130 (2.31%) 3	2 / 132 (1.52%) 2	0 / 129 (0.00%) 0
Fall subjects affected / exposed occurrences (all)	4 / 130 (3.08%) 4	5 / 132 (3.79%) 5	4 / 129 (3.10%) 4
Ligament sprain subjects affected / exposed occurrences (all)	0 / 130 (0.00%) 0	0 / 132 (0.00%) 0	0 / 129 (0.00%) 0
Limb injury subjects affected / exposed occurrences (all)	0 / 130 (0.00%) 0	1 / 132 (0.76%) 1	2 / 129 (1.55%) 2
Procedural pain subjects affected / exposed occurrences (all)	2 / 130 (1.54%) 2	0 / 132 (0.00%) 0	0 / 129 (0.00%) 0
Traumatic haematoma subjects affected / exposed occurrences (all)	1 / 130 (0.77%) 1	2 / 132 (1.52%) 2	2 / 129 (1.55%) 2
Cardiac disorders			
Atrioventricular block first degree subjects affected / exposed occurrences (all)	1 / 130 (0.77%) 1	0 / 132 (0.00%) 0	0 / 129 (0.00%) 0
Bundle branch block left			

subjects affected / exposed	0 / 130 (0.00%)	0 / 132 (0.00%)	3 / 129 (2.33%)
occurrences (all)	0	0	3
Bundle branch block right			
subjects affected / exposed	1 / 130 (0.77%)	0 / 132 (0.00%)	2 / 129 (1.55%)
occurrences (all)	1	0	2
Sinus bradycardia			
subjects affected / exposed	0 / 130 (0.00%)	3 / 132 (2.27%)	2 / 129 (1.55%)
occurrences (all)	0	3	2
Sinus tachycardia			
subjects affected / exposed	0 / 130 (0.00%)	0 / 132 (0.00%)	2 / 129 (1.55%)
occurrences (all)	0	0	2
Ventricular extrasystoles			
subjects affected / exposed	0 / 130 (0.00%)	0 / 132 (0.00%)	2 / 129 (1.55%)
occurrences (all)	0	0	2
Nervous system disorders			
Amnesia			
subjects affected / exposed	0 / 130 (0.00%)	0 / 132 (0.00%)	0 / 129 (0.00%)
occurrences (all)	0	0	0
Dementia Alzheimer's type			
subjects affected / exposed	0 / 130 (0.00%)	2 / 132 (1.52%)	0 / 129 (0.00%)
occurrences (all)	0	2	0
Dizziness			
subjects affected / exposed	3 / 130 (2.31%)	2 / 132 (1.52%)	0 / 129 (0.00%)
occurrences (all)	3	4	0
Dizziness exertional			
subjects affected / exposed	3 / 130 (2.31%)	0 / 132 (0.00%)	0 / 129 (0.00%)
occurrences (all)	3	0	0
Dizziness postural			
subjects affected / exposed	2 / 130 (1.54%)	2 / 132 (1.52%)	3 / 129 (2.33%)
occurrences (all)	2	2	3
Headache			
subjects affected / exposed	8 / 130 (6.15%)	5 / 132 (3.79%)	7 / 129 (5.43%)
occurrences (all)	8	5	9
Tension headache			
subjects affected / exposed	3 / 130 (2.31%)	0 / 132 (0.00%)	4 / 129 (3.10%)
occurrences (all)	3	0	4

Blood and lymphatic system disorders			
Iron deficiency anaemia			
subjects affected / exposed	2 / 130 (1.54%)	1 / 132 (0.76%)	0 / 129 (0.00%)
occurrences (all)	2	1	0
Leukopenia			
subjects affected / exposed	2 / 130 (1.54%)	3 / 132 (2.27%)	0 / 129 (0.00%)
occurrences (all)	2	4	0
Normochromic normocytic anaemia			
subjects affected / exposed	2 / 130 (1.54%)	0 / 132 (0.00%)	0 / 129 (0.00%)
occurrences (all)	2	0	0
Ear and labyrinth disorders			
Tinnitus			
subjects affected / exposed	0 / 130 (0.00%)	0 / 132 (0.00%)	0 / 129 (0.00%)
occurrences (all)	0	0	0
Vertigo positional			
subjects affected / exposed	0 / 130 (0.00%)	2 / 132 (1.52%)	1 / 129 (0.78%)
occurrences (all)	0	2	1
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	0 / 130 (0.00%)	1 / 132 (0.76%)	1 / 129 (0.78%)
occurrences (all)	0	1	1
Abdominal pain upper			
subjects affected / exposed	1 / 130 (0.77%)	3 / 132 (2.27%)	0 / 129 (0.00%)
occurrences (all)	1	3	0
Constipation			
subjects affected / exposed	0 / 130 (0.00%)	0 / 132 (0.00%)	0 / 129 (0.00%)
occurrences (all)	0	0	0
Diarrhoea			
subjects affected / exposed	8 / 130 (6.15%)	2 / 132 (1.52%)	6 / 129 (4.65%)
occurrences (all)	8	2	6
Diverticulum intestinal			
subjects affected / exposed	0 / 130 (0.00%)	0 / 132 (0.00%)	2 / 129 (1.55%)
occurrences (all)	0	0	2
Dry mouth			
subjects affected / exposed	0 / 130 (0.00%)	3 / 132 (2.27%)	1 / 129 (0.78%)
occurrences (all)	0	3	1
Gastritis			

subjects affected / exposed occurrences (all)	1 / 130 (0.77%) 1	2 / 132 (1.52%) 2	2 / 129 (1.55%) 2
Nausea subjects affected / exposed occurrences (all)	7 / 130 (5.38%) 8	4 / 132 (3.03%) 4	6 / 129 (4.65%) 6
Vomiting subjects affected / exposed occurrences (all)	2 / 130 (1.54%) 2	3 / 132 (2.27%) 3	2 / 129 (1.55%) 2
Hepatobiliary disorders Cholelithiasis subjects affected / exposed occurrences (all)	2 / 130 (1.54%) 2	0 / 132 (0.00%) 0	0 / 129 (0.00%) 0
Hepatic steatosis subjects affected / exposed occurrences (all)	0 / 130 (0.00%) 0	2 / 132 (1.52%) 2	1 / 129 (0.78%) 1
Renal and urinary disorders Urinary incontinence subjects affected / exposed occurrences (all)	1 / 130 (0.77%) 1	1 / 132 (0.76%) 1	1 / 129 (0.78%) 1
Musculoskeletal and connective tissue disorders Arthralgia subjects affected / exposed occurrences (all)	4 / 130 (3.08%) 4	1 / 132 (0.76%) 1	1 / 129 (0.78%) 1
Musculoskeletal stiffness subjects affected / exposed occurrences (all)	0 / 130 (0.00%) 0	0 / 132 (0.00%) 0	0 / 129 (0.00%) 0
Osteoarthritis subjects affected / exposed occurrences (all)	0 / 130 (0.00%) 0	2 / 132 (1.52%) 2	1 / 129 (0.78%) 2
Infections and infestations Bronchitis subjects affected / exposed occurrences (all)	2 / 130 (1.54%) 2	3 / 132 (2.27%) 3	2 / 129 (1.55%) 2
Bronchitis bacterial subjects affected / exposed occurrences (all)	0 / 130 (0.00%) 0	0 / 132 (0.00%) 0	2 / 129 (1.55%) 2

Bronchitis viral			
subjects affected / exposed	0 / 130 (0.00%)	2 / 132 (1.52%)	0 / 129 (0.00%)
occurrences (all)	0	3	0
Cystitis			
subjects affected / exposed	2 / 130 (1.54%)	1 / 132 (0.76%)	0 / 129 (0.00%)
occurrences (all)	2	1	0
Gastroenteritis			
subjects affected / exposed	0 / 130 (0.00%)	0 / 132 (0.00%)	2 / 129 (1.55%)
occurrences (all)	0	0	2
Influenza			
subjects affected / exposed	1 / 130 (0.77%)	1 / 132 (0.76%)	6 / 129 (4.65%)
occurrences (all)	1	1	6
Nasopharyngitis			
subjects affected / exposed	0 / 130 (0.00%)	0 / 132 (0.00%)	0 / 129 (0.00%)
occurrences (all)	0	0	0
Periodontitis			
subjects affected / exposed	2 / 130 (1.54%)	1 / 132 (0.76%)	2 / 129 (1.55%)
occurrences (all)	2	1	2
Rhinitis			
subjects affected / exposed	0 / 130 (0.00%)	1 / 132 (0.76%)	1 / 129 (0.78%)
occurrences (all)	0	1	1
Urinary tract infection			
subjects affected / exposed	0 / 130 (0.00%)	1 / 132 (0.76%)	7 / 129 (5.43%)
occurrences (all)	0	1	10
Viral upper respiratory tract infection			
subjects affected / exposed	5 / 130 (3.85%)	9 / 132 (6.82%)	6 / 129 (4.65%)
occurrences (all)	5	13	7
Metabolism and nutrition disorders			
Acquired mixed hyperlipidaemia			
subjects affected / exposed	1 / 130 (0.77%)	1 / 132 (0.76%)	2 / 129 (1.55%)
occurrences (all)	1	1	2
Decreased appetite			
subjects affected / exposed	6 / 130 (4.62%)	3 / 132 (2.27%)	1 / 129 (0.78%)
occurrences (all)	6	3	1
Dyslipidaemia			

subjects affected / exposed	2 / 130 (1.54%)	0 / 132 (0.00%)	0 / 129 (0.00%)
occurrences (all)	2	0	0
Glucose tolerance impaired			
subjects affected / exposed	0 / 130 (0.00%)	2 / 132 (1.52%)	0 / 129 (0.00%)
occurrences (all)	0	2	0
Hypercholesterolaemia			
subjects affected / exposed	4 / 130 (3.08%)	2 / 132 (1.52%)	1 / 129 (0.78%)
occurrences (all)	4	2	1
Hyperglycaemia			
subjects affected / exposed	4 / 130 (3.08%)	2 / 132 (1.52%)	0 / 129 (0.00%)
occurrences (all)	4	2	0
Hypertriglyceridaemia			
subjects affected / exposed	0 / 130 (0.00%)	2 / 132 (1.52%)	3 / 129 (2.33%)
occurrences (all)	0	2	3
Hyperuricaemia			
subjects affected / exposed	2 / 130 (1.54%)	0 / 132 (0.00%)	1 / 129 (0.78%)
occurrences (all)	2	0	1
Hypoglycaemia			
subjects affected / exposed	0 / 130 (0.00%)	0 / 132 (0.00%)	0 / 129 (0.00%)
occurrences (all)	0	0	0
Hypokalaemia			
subjects affected / exposed	2 / 130 (1.54%)	1 / 132 (0.76%)	0 / 129 (0.00%)
occurrences (all)	2	1	0
Hyponatraemia			
subjects affected / exposed	2 / 130 (1.54%)	3 / 132 (2.27%)	1 / 129 (0.78%)
occurrences (all)	2	3	2
Malnutrition			
subjects affected / exposed	2 / 130 (1.54%)	2 / 132 (1.52%)	0 / 129 (0.00%)
occurrences (all)	2	2	0
Type 2 diabetes mellitus			
subjects affected / exposed	1 / 130 (0.77%)	2 / 132 (1.52%)	2 / 129 (1.55%)
occurrences (all)	1	2	2

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
05 February 2015	Update of the inclusion criterion related to estimated Glomerular Filtration Rate (GFR) calculation.
09 December 2015	During the optional extension period, the decrease of donepezil dose from 10 mg to 5 mg was permitted if necessary between weeks 28 and 38. Once dose of donepezil decreased to 5 mg, the investigator did not have the possibility to return to 10 mg.
29 February 2016	Recruitment in Japan was closed further to recruitment difficulties. New countries were added to the list of participating countries in order to reach the planned target of total patients.
10 November 2016	Update of the list of concomitant treatments with addition of BCRP substrates.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? Yes

Date	Interruption	Restart date
26 June 2017	The main analysis was done in June 2017 with full efficacy and safety data of the mandatory 24-week treatment period. Based on these results, the Sponsor decided to discontinue the study and the development of S47445 in Alzheimer's Disease.	-

Notes:

Limitations and caveats

None reported